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Summary 
Mitochondria are unique cell organelles, also called the powerhouses of our cells, which play 
a central role in human oxygen metabolism and general energy supply. By creating 
biologically accessible energy, these organelles sustain the maintenance of metabolic 
function and homeostasis. Therefore, accurate function of mitochondria is crucial to proper 
skeletal muscle operations as well as to general human health. Already small alterations or 
defects of mitochondria may have deleterious effects, which could play an important role in 
the process of aging and in several neuromuscular and neurodegenerative diseases such as 
Huntington disease, and in particular in mitochondrial cytopathies. Although the importance 
of proper mitochondrial function for human health and skeletal muscle functioning has been 
recognized, a comprehensive understanding of the regulations and the underlying 
mechanisms especially in relation to aging and the development of various neuromuscular 
diseases is lacking.  
Accordingly, the aim of this comprehensive PhD project was to investigate mitochondrial 
function and its relation to other skeletal muscle properties in healthy young and old 
individuals and in patients with disorders that may affect skeletal muscle mitochondria such 
as mitochondrial myopathy and Huntington disease. Therefore, high-resolution respirometry 
measurements of permeabilized skeletal muscle fibers were conducted. The application of 
this method thereby allows the preservation of innate mitochondrial function and represents 
the highest standard approach for the characterisation of mitochondrial function.  
Regarding mitochondrial characteristics, the three independent studies included in this 
dissertation revealed the following key findings: 1) Maximal fatty acid oxidative capacity was 
higher in healthy old compared to fitness-level-matched young individuals, 2) mitochondrial 
respiratory capacity of each complex as well as mitochondrial volume density was lower in 
patients with mitochondrial myopathy and 3) patients with Huntington disease were 
characterized by lower complex I respiratory and maximal oxidative phosphorylation capacity 
compared to healthy controls. Consequently, the present findings contribute to the general 
understanding of mitochondrial characteristics, potential regulatory mechanisms and 
adaptations to varying circumstances. Together with previous and future studies these 
results may potentially lead to the development of effective therapeutic strategies in order to 
improve mitochondrial function and life quality in aged people as well as in patients with 
neuromuscular or neurodegenerative diseases.  
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Zusammenfassung 
Mitochondrien sind einzigartige Zellorganellen und spielen eine zentrale Rolle im 
menschlichen Sauerstoffmetabolismus sowie der generellen Energiebereitstellung. Nicht 
zuletzt deshalb werden sie auch als Kraftwerke unserer Zellen bezeichnet. Die Bereitstellung 
biologisch nutzbarer Energie durch diese Organellen dient dabei der Aufrechterhaltung der 
metabolischen Funktionen unseres Körpers sowie der Homöostase. Gerade deshalb ist ihre 
Intaktheit sowohl für jegliche Funktionen der Skelettmuskulatur als auch für die allgemeine 
menschliche Gesundheit entscheidend. Bereits kleine Abweichungen oder Defekte der 
Mitochondrien bzw. ihrer Funktionsweise  können schwerwiegende Folgen nach sich ziehen, 
welche nicht nur den Alterungsprozess aber auch die Entstehung und den Verlauf von 
neuromuskulären und neurodegenerativen Krankheiten wie der Huntington-Krankheit und 
insbesondere auch mitochondriale Zytopathien betreffen. Obwohl die Bedeutung der intakten 
mitochondrialen Funktion für die menschliche Gesundheit sowie derjenigen der 
Skelettmuskulatur weitgehend bekannt ist, fehlt bis heute ein ganzheitliches Verständnis für 
die Regulationen und die zugrundeliegenden Mechanismen, speziell in Bezug auf den 
Alterungsprozess und die Entstehung neuromuskulärer Krankheiten.  
Das Ziel dieses umfassenden PhD-Projektes war es deshalb, die mitochondriale Funktion 
sowie deren Relation zu anderen Skelettmuskeleigenschaften sowohl in gesunden jungen 
und älteren Individuen als auch in Patienten mit Krankheiten wie der mitochondrialen 
Myopathie oder der Huntington-Krankheit, welche die Mitochondrien der Skelettmuskulatur 
betreffen können, zu untersuchen. Die Untersuchungen wurden dabei mit Hilfe hoch-
auflösender respirometrischen Messungen in permeabilisierten Skelettmuskelfasern 
durchgeführt. Diese Methode erlaubt es, die ursprüngliche Funktionsweise der Mitochondrien 
zu erhalten und repräsentiert zugleich den höchsten Standard für die Charakterisierung der 
Mitochondrien.  
Bezüglich mitochondrialer Funktion führten die drei unabhängigen Studien der vorliegenden 
Dissertation zu folgenden Hauptbefunden: 1) Die maximale Fettoxidationsrate der 
Mitochondrien der Skelettmuskulatur von älteren Individuen war höher als diejenige von 
jungen in vergleichbarem Fitnesszustand, 2) die mitochondriale respiratorische Kapazität 
jedes einzelnen Komplexes sowie die mitochondriale Volumendichte waren tiefer in 
Patienten mit mitochondrialer Myopathie und 3) Huntington-Patienten wiesen im Vergleich zu 
gesunden Kontrollpersonen tiefere Komplex I Aktivität sowie tiefere maximale oxidative 
Phosphorylierungs-Kapazität auf. Folglich tragen die vorliegenden Resultate zum generellen 
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Verständnis mitochondrialer Charakteristika, potentieller regulatorischer Mechanismen sowie 
Anpassungen an verschiedene Situationen bei. Die hier präsentierten Resultate könnten 
zusammen mit früheren und zukünftigen Studienergebnissen zur Entwicklung von effektiven 
therapeutischen Strategien führen, welche die mitochondriale Funktion sowie die 
Lebensqualität von älteren Menschen sowie Patienten mit neuromuskulären oder 
neurodegenerativen Krankheiten verbessern könnten. 
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1. Introduction 
1.1 Metabolism and energy supply 
Metabolism describes the entirety of all energy transformations in the human organism. In 
order to provide the organism with energy, which is critical for all cellular activities and 
homeostasis, the energy from nutrients needs to be transformed into chemical energy. 
Appropriate energy supply is also needed for skeletal muscle activity, irrespective of duration 
and intensity. The human organism obeys the first law of thermodynamics stating that energy 
is only converted but neither created or destroyed and represents an open thermodynamic 
system. Accordingly, the chemical energy from nutrients including carbohydrates, fats and 
proteins is stored as adenosine triphosphate (ATP) and subsequently transferred to energy 
for physiological functions such as muscular contraction. Thereby, some of the energy is 
used to conduct physical work but the majority is converted into heat.  
The ATP content of skeletal muscle at rest is approximately 25 mmol kg−1 dry muscle 
(Soderlund & Hultman, 1990), which lasts for only a few seconds of contraction. Generally, 
the ATP stored in the organism at any given time is only sufficient for a few minutes of 
physiological function. Hence, ATP needs to be constantly resynthesized from ADP that can 
be realized by interactions of ADP with creatine phosphate, anaerobic glycolysis and aerobic 
respiration in the cell mitochondria. For their energetically demanding functions as 
contraction and protein synthesis, skeletal muscle fibers require large amounts of ATP which 
are particularly provided by mitochondria.  
 
1.2 Mitochondrial structure  
Mitochondria are cellular organelles that occupy a substantial proportion of the cytoplasm of 
eukaryotic cells. Usually, they are described as bean-shaped, stiff, elongated cylinders with a 
diameter of 0.5 – 1 µm, resembling bacteria (Alberts et al., 2002).  
These cell organelles consist of an outer mitochondrial membrane that is permeable to small 
molecules and ions and separates the mitochondrial intermembrane space from the 
cytoplasm. In contrast, the inner membrane is highly specialized and impermeable to most 
small molecules and ions, including protons. The only known transport across the inner 
membrane from matrix to intermembrane space and vice versa occurs through specific 
transporters. The inner membrane bears the respiratory chain or electron transport chain 
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(ETC, complex I-IV) and the ATP synthase (complex V) and encloses the mitochondrial 
matrix. The ETC itself consists of a series of sequentially acting membrane-embedded multi-
enzyme complexes that serve as electron carriers. The inner membrane is also 
characterized by a series of invaginations, so called cristae, which increase its surface area 
and project into the matrix. The mitochondrial matrix thereby contains the pyruvate 
dehydrogenase complex, the enzymes of the tricarboxylic acid cycle (TCA), the fatty acid β-
oxidation pathway and the pathways of amino acid oxidation. Noteworthy, the matrix also 
contains the mitochondrial genome. 
Mitochondria contain their own genome, the mitochondrial DNA (mtDNA). The human 
mitochondrial genome is an exclusively maternally inherited double-stranded circular 
molecule. Each organelle generally contains several identical copies of mtDNA. The mtDNA-
encoded polypeptides are all subunits of the enzyme complexes of the ETC. Enzymes of the 
various metabolic pathways are encoded by nuclear DNA (nDNA). Noteworthy, even the 
complexes of the ETC are of hybrid origin (Taanman, 1999). Thus, as mitochondria are 
controlled by mtDNA and nDNA, mutations within either DNA may result in ETC deficiency 
resulting in different mitochondrial disorders (Tuppen et al., 2010).  
Mitochondria  are mobile and plastic organelles, changing their shape by fusion and fission 
(Westermann, 2010). These organelles move in the cytoplasm and are often associated with 
microtubules, which determine their unique orientation and distribution in different cell types 
(Alberts et al., 2002). Two morphologically and biochemically distinct populations of skeletal 
muscle mitochondria can be described: subsarcolemmal (SS) mitochondria and 
intermyofibrillar (IMF) mitochondria (Müller, 1976; Picard et al., 2013).  Morphologically, SS 
mitochondria rather appear as isolated spherical units and IMF mitochondria are organized 
as interconnected reticular networks (Figure 1, Kirkwood et al., 1986; Ogata & Yamasaki, 
1997; Picard et al., 2013). Subsarcolemmal mitochondria are near the capillary and thought 
to be involved in providing the energy required for the transport of O2 from the erythrocyte 
into the muscle cell (Müller, 1976). In contrast, IMF mitochondria are suggested to provide 
the energy required for contractile protein interaction and therefore muscular contraction 
(Müller, 1976). Moreover, mitochondrial shape and configuration are distinctive for each 
human skeletal muscle fiber type (Ogata & Yamasaki, 1997). Collectively, mitochondria are 
able to change their configuration in response to cellular metabolism and adapt to varying 
circumstances, which is critical for maintaining mitochondrial function (Hoppeler & Flück, 
2003; Youle & van der Bliek, 2012; Boushel et al., 2014). Thus, mitochondrial morphology 
and its regulation are distinctively connected with mitochondrial function. 
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Figure 1. Subsarcolemmal and intermyofibrillar mitochondrial morphology. Electron microscopic 
image of a freeze-fractured intact mouse soleus muscle. Cap, capillary; Myofibr, myofibrils; PM, 
plasma membrane; S, sarcomeres. (modified from Picard et al., 2013) 
 
1.3 Mitochondria and their critical role in energy supply  
The primary production of ATP is achieved by cellular respiration in the mitochondria. 
Cellular respiration describes the molecular process by which cells consume O2 and produce 
CO2, occurring in three major stages (Nelson & Cox, 2008). Firstly, glucose, fatty acids and 
some amino acids are oxidized to acetyl-coenzyme A (acetyl-CoA). Secondly, acetyl-CoA 
enters the TCA (Figure 2), whereby acetyl-CoA is oxidized to CO2 and the released energy is 
conserved in the form of NADH and FADH2. Thirdly, NADH and FADH2 are oxidized. 
Thereby, the electrons are transferred to O2 via the ETC. The amount of energy released is 
conserved as ATP by a process named oxidative phosphorylation (Nelson & Cox, 2008).    
Oxidative phosphorylation is regulated by cellular energy demands and described by three 
main processes (Figure 3): 1) flow of electrons through a chain of membrane-bound carriers, 
2) coupling of exergonic electron flow out of the matrix into the intermembrane space to 
endergonic transport of protons across the inner membrane, thereby conserving the energy 
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as a transmembrane electrochemical potential, and 3) the transmembrane flow of protons 
down their concentration gradient that provides the energy for the synthesis of ATP by ATP 
synthase, a membrane-bound protein complex that couples proton flow to phosphorylation of 
ADP (Mitchell, 1961; Nelson & Cox, 2008).   
 
 
 
 
 
 
 
 
 
 
Figure 2. The tricarboxylic acid cycle (TCA). Acetyl-CoA is oxidized to CO2 and the released energy 
is conserved in NADH and FADH2. The TCA itself produces one ATP (or GTP) at each turn. (modified 
from Nelson & Cox, 2008)  
 
The pumping of protons across the inner membrane results in a pH gradient with a higher pH 
in the matrix than in the intermembrane space and a voltage gradient (the membrane 
potential), with a negatively charged matrix and a positively charged intermembrane space. 
Together the gradients build the so called electrochemical proton gradient, which exerts a 
proton motive force and drives the ATP synthesis in the process of oxidative phosphorylation 
(Alberts et al., 2002).   
Oxidative phosphorylation starts with the entrance of electrons into the ETC. Electron input 
thereby occurs from the following four sources (Figure 4): 1) NADH, 2) TCA specific FADH2 
(succinate), 3) electrons from metabolized fatty-acids through the electron-transferring 
flavoprotein (ETF), and 4) electrons from glycerol 3-phosphate. All electrons are transferred 
to ubiquinone (Q).  
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Figure 3. The respiratory chain. Simple representation of the chemiosmotic theory applied to 
mitochondria. The transmembrane differences in protein concentration are the reservoir for the energy 
that is extracted from biological oxidation reactions. (modified from Nelson & Cox, 2008)  
 
 
Figure 4. Electron input into the mitochondrial respiratory chain from NADH, succinate, fatty 
acyl-CoA and glycerol 3-phosphate to ubiquinone (Q). Electrons from NADH pass through 
complex I and electrons from succinate through complex II to Q. Electrons from β-oxidation are 
transferred to electron-transferring flavoprotein (ETF) that passes them to Q. (modified from Nelson & 
Cox, 2008)  
 
In Complex I (CI) electrons are transferred from NADH to Q whereby simultaneously protons 
are pumped from the matrix into the intermembrane space. Complex II (CII) is the only 
membrane-bound enzyme of the TCA and thereby allows the electron transfer from 
succinate via FAD to Q. Other substrates pass electrons into the ETC at the level of Q either 
via FAD and ETF or by glycerol 3-phosphate dehydrogenase (Figure 4). Reduced Q (QH2) is 
subsequently reoxidized by Complex III (CIII). Accordingly, CIII couples the transport of 
electrons from QH2 to cytochrome C (CytC), a soluble protein of the intermembrane space. 
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As a result, CytC donates the electron to complex IV (CIV). Finally, CIV, better known as 
cytochrome c oxidase (COX), carries electrons from CytC to O2 and reduces O2 to H2O. In 
total, for each pair of electrons transferred to O2, four protons are pumped out by CI, four by 
CIII and two by CIV (Figure 3), resulting in the previously described proton motive force. This 
proton motive force in turn drives the synthesis of ATP from ADP and Pi by complex V (CV), 
also called ATP synthase. Several steps in the path of oxidative phosphorylation have the 
potential to produce reactive oxygen species (ROS) that can damage cells. When the rate of 
electron entry into the ETC and the rate of electron transfer through the ETC are 
mismatched, superoxide radical production increases at CI and CIII. These potentially 
harmful ROS can to a certain amount be inactivated by a set of protective enzymes as 
superoxide dismutase (Nelson & Cox, 2008).  
Fundamentally, skeletal muscle fibers are densely populated with these organelles and are 
able to substantially increase their ATP production during maximal contraction (Bangsbo et 
al., 2001). Thus, proper functioning mitochondria represent an essential requirement for 
sustained ATP production in order to maintain physiological homeostasis and skeletal 
muscle work.  
 
1.4 Mitochondrial function and its critical role in human physiology 
In addition to energy supply, mitochondria have several other functions in specific tissues 
and under distinct circumstances that are also crucial for the maintenance of homeostasis 
and human health. Amongst others, mitochondria are the sites of steroid hormone synthesis 
(Miller, 2013), they control cytosolic calcium concentration (Pozzan et al., 2000) and regulate 
apoptotic cell death (Newmeyer & Ferguson-Miller, 2003). The primary function of 
mitochondria, however, is the production of ATP by oxidative phosphorylation, as described 
above. When referring to mitochondrial function throughout this dissertation, this specifically 
refers to the bioenergetic characteristics in human skeletal muscle mitochondria. 
Mitochondria are dynamic subcellular structures and continuously adapt to their actual 
environment by alterations of size and number (Hoppeler & Flück, 2003; Youle & van der 
Bliek, 2012; Boushel et al., 2014). The important role of this organelle in metabolic 
homeostasis represents both a blessing and a curse. On the one hand, metabolic stress like 
exercise can positively influence mitochondrial function (Jacobs et al., 2013; Boushel et al., 
2014) but on the other hand, already small alterations or little damage of those organelles 
can have severe consequences on human health (Zeviani & Di Donato, 2004; Tuppen et al., 
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2010). Nowadays, the importance of proper mitochondrial function in relation to muscle 
physiology is undisputed. Nonetheless, several skeletal muscle mitochondrial characteristics 
especially their role in the process of aging and different diseases are not completely 
understood. Revealing the mechanisms regulating mitochondrial characteristics and their 
relations to other skeletal muscle properties could be crucial to further increase the present 
understanding of mitochondrial and muscle physiology and pathophysiology, respectively.  
Accordingly, investigating mitochondrial function and its adaptation to distinct stimuli or 
changing circumstances, respectively, is of great importance in the understanding of the 
process of aging and several diseases affecting the muscle and nervous system such as 
mitochondrial myopathy (MM) and Huntington disease (HD).  
The investigation of skeletal muscle mitochondrial function and its relations to human health 
including the process of aging and disease require the administration of sensitive and reliable 
functional measures. Classic studies have measured function from maximal respiratory 
capacity in isolated mitochondria, which provides a mechanistic insight in mitochondrial 
characteristics. However, the state-of-the-art in this field is a twin-chamber instrument called 
Oroboros Oxygraph-2k (Oroboros Instruments, Innsbruck, Austria), which only needs small 
tissue amounts and is highly sensitive (Gnaiger, 2009; Lanza & Nair, 2010). Moreover, this 
approach allows the assessment of respiratory capacity at multiple levels of the respiratory 
chain, serial measurements in the same tissue sample and the determination of oxidative 
phosphorylation efficiency (Gnaiger, 2001). All studies of this dissertation applied in vitro 
high-resolution respirometric assessments of skeletal muscle mitochondrial function. Since 
mitochondrial isolation procedures may disrupt the functional structural network and alter 
innate mitochondrial characteristics (Picard et al., 2011), measures were conducted in 
permeabilized myofibers. Hence, high-resolution respirometry measurements in 
permeabilized fibers allow the preservation of innate mitochondrial function and represent the 
highest standard approach for the investigation of mitochondrial characteristics. In order to 
provide a qualitative index of mitochondrial function, polarographic measurements of O2 
consumption are frequently normalized to mitochondrial content. Accordingly, accurate 
determination of mitochondrial content is crucial to any measure of intrinsic mitochondrial 
function. Two-dimensional imaging using transmission electron microscopy (TEM) is 
regarded as the gold standard to assess mitochondrial content. However, since TEM 
measurements are time consuming and are not available for many laboratories, biomarkers 
have often been applied as a surrogate for mitochondrial content. These biomarkers include 
mitochondrial enzyme activities such as citrate synthase (CS) or COX and have become 
widely accepted, despite varying correlations with TEM-assessed mitochondrial content 
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(Larsen et al., 2012). In the present studies, different methods for the assessment of 
mitochondrial content have been applied, including the gold standard of TEM as well as two 
different biomarkers.  
The following subsections briefly elucidate the specific reasons for the conductance of the 
three studies included in the present dissertation. The detailed background information, 
methods, results and conclusions are presented in the manuscript section. The manuscripts 
are to date in second revision, ready to submit or in preparation for submission. 
 
1.4.1 Aging, efficiency and skeletal muscle mitochondrial function 
Exercise efficiency (EE) describes the effectiveness of the human body in converting energy 
from nutrients into external work and is therefore defined as the ratio of work performed to 
the amount of oxygen consumed (Gaesser & Brooks, 1975). In the present literature there is 
still debate about whether and in which direction EE is altered with aging (Ortega, 2013; 
Venturelli & Richardson, 2013). A possible explanation for the ongoing discussion and for the 
discrepancies between previous findings could be varying fitness level of the study 
participants. In general, old individuals are suggested to be less trained than young 
individuals (Russ & Kent-Braun, 2004; Amati et al., 2008; Gram et al., 2014), which could 
introduce a bias as EE has been demonstrated to differ between trained and untrained 
individuals (Hopker et al., 2013) and to be improved with exercise training (Woo et al., 2006; 
Montero & Lundby, 2015). Additionally, peak O2 uptake (V̇O2peak) declines at a rate of 
approximately 4.0 mL kg−1 min−1 (8 %) per decade due to differences in maximum heart rate 
(Wilson & Tanaka, 2000). The first aim of this study was to determine EE in fitness-level-
matched young and old individuals to test the hypothesis that EE is higher in the old 
population. In order to match the participants by similar fitness level, V̇O2peak was adjusted for 
age in advance (Wilson & Tanaka, 2000). The second aim of this study was to elucidate the 
potential sources for the expected differences with age. We hypothesized that the ratio of 
slow-twitch (ST) to fast-twitch (FT) fiber is higher in old individuals. Moreover, we assumed 
that mitochondrial function is preserved with age when controlling for fitness level, however, 
mitochondrial content is higher according to higher ST fiber proportion, which could explain a 
higher EE with advanced age. 
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1.4.2 Mitochondrial myopathy (MM) and skeletal muscle mitochondrial function 
Mitochondrial cytopathies (MC) are a group of clinically heterogeneous diseases, commonly 
defined by a lack of cellular energy (Tuppen et al., 2010). MC are caused by mutations of 
mtDNA and/or nDNA, which encode for mitochondrial proteins (Wallace, 1999) and may 
therefore lead to defects in either one or several mitochondrial metabolic pathways including 
the respiratory chain and oxidative phosphorylation. Besides central-nervous system 
manifestations, MC also include neuromuscular manifestations such as myopathy and 
peripheral neuropathy (Taylor & Turnbull, 2005). Specifically, the affection of skeletal muscle 
is defined as mitochondrial myopathy (MM) and represents a common manifestation of MC, 
either as isolated MM or in combination with other symptoms of MC (Di Mauro, 2004). 
Despite constant progress in understanding the biochemistry and genetics of MM, 
pathophysiological mechanisms have remained elusive and proven cures as well as distinct 
diagnostic criteria are lacking (Di Mauro, 2010; Hassani et al., 2010). Defects in the muscle 
oxidative phosphorylation cascade could result in exercise intolerance and muscle fatigue, 
often reported symptoms, leading to substantially impaired quality of life and a sedentary 
lifestyle (Taivassalo & Haller, 2004). The latter could in turn further decrease the level of 
functional mitochondria. Therefore, the purpose of this study was to determine mitochondrial 
function in patients with MM in comparison to healthy age- and gender-matched individuals. 
In order to being able to characterize mitochondrial function and potential pathomechanisms, 
we aimed to assess the respiratory capacity of each single complex.  
 
1.4.3  Huntington disease (HD) and skeletal muscle mitochondrial function 
Huntington disease (HD) is an autosomal-dominant, progressive neurodegenerative disorder 
with various symptoms including cognitive, behavioural and motor dysfunction (Martin & 
Gusella, 1986; Walker, 2007). HD is caused by mutated huntingtin, which results from an 
expanded CAG trinucleotide repeat leading to a poly-glutamine strand of variable length (The 
Huntington's Disease Collaborative Research Group, 1993). To date, it is suggested that this 
poly-glutamine stretch confers a toxic gain of function. However, precise pathophysiological 
mechanisms are not fully understood (Walker, 2007). Accordingly, therapeutic approaches 
that slow the progressive dysfunction are currently unavailable. Considering the involvement 
of the motor system, thorough analysis of skeletal muscle properties could offer promising 
insights into potential pathomechanisms in peripheral tissue. First studies indicate a deficit of 
in vivo mitochondrial oxidative metabolism, supporting the role of mitochondrial dysfunction 
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as a factor in the pathogenesis of HD (Lodi et al., 2000; Saft et al., 2005). Therefore, the aim 
of this study was to investigate potential alterations in vitro mitochondrial respiratory capacity 
of each complex and in skeletal muscle morphology of patients with HD. We hypothesized 
that HD also affects and manifests in peripheral tissue, in addition to the already known 
central-nervous system manifestations. These investigations could thereby offer new insights 
into the pathogenic mechanisms which could in the future lead to new therapeutic 
approaches.  
 
In conclusion, the main purpose of the present PhD project was to generate a 
comprehensive assessment of mitochondrial function by investigating mitochondrial function 
in healthy young and old individuals and in patients with diseases including mitochondrial 
affections such as MM and HD. Another aim of this study was to investigate the relations of 
mitochondrial function to other muscle physiological parameters as exercise performance, 
exercise efficiency and muscle phenotype. A potential implication could be the enhancement 
of diagnostic and classification measures of MM, as these presently require a multifaceted 
approach of numerous methods (Tarnopolsky & Raha, 2005). Last but not least, effective 
treatment approaches for MM and HD are currently lacking (Di Mauro, 2010; Hassani et al., 
2010), thus novel therapeutic treatments are urgently needed. Therefore, the present aspired 
contribution to the understanding of the molecular basis of these conditions may support the 
development of novel therapeutic strategies to improve mitochondrial function and to delay 
the onset of (age-related) diseases in the future.  
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Abstract 
Purpose Whether exercise efficiency (EE) becomes elevated with age is debated and the 
underlying mechanisms remain disputed. Thus, the aim of this study was to determine if EE 
is higher in old humans and whether these potential differences may be attributed to skeletal 
muscle properties. Methods EE was assessed in 11 young (27 ± 4 yr) and 12 old (66 ± 4 yr) 
individuals of matched fitness levels. Skeletal muscle biopsies were obtained from the m. 
vastus lateralis for the assessment of fiber type distribution, citrate synthase activity and 
mitochondrial function. Leg mass was determined by dual-energy X-ray absorptiometry. 
Results EE was higher (P < 0.01) in old (16.7 ± 1.5 %) than young (14.0 ± 2.4 %) 
individuals, whereas leg mass was similar (P = 0.457). Also percentage slow- and fast-twitch 
fiber distribution did not differ (61.3 ± 11.7 vs. 53.4 ± 10.9 % and 38.7 ± 11.7 vs. 46.6 ± 10.9 
%, P = 0.161). Similarly, citrate synthase activity, maximal mitochondrial oxidative 
phosphorylation capacity and measures of mitochondrial efficiency did not differ. 
Submaximal respiratory exchange ratio was however lower (P < 0.001) in the old (0.80 ± 
0.06 and 0.95 ± 0.07, respectively), which coincided with higher (P < 0.001) maximal fatty 
acid oxidative capacity (36.2 ± 9.9 vs. 20.5 ± 3.7 pmol O2 mg−1 s−1) and that revealed a 
positive correlation with EE (P < 0.01). Conclusions EE is higher in older individuals when 
matched for fitness level and is correlated with fatty acid oxidative capacity. 
 
Keywords 
Aging; bioenergetics; mitochondrial function; whole body economy 
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Abbreviations 
AU, arbitrary unit; BMR, basal metabolic rate; BSA, bovine serum albumin; COX, respiratory 
capacity of complex IV; CS, citrate synthase; DE, delta efficiency; DXA, dual-energy X-ray 
absorptiometry; E, electron transport system capacity; EC, exercise economy; EE, exercise 
efficiency; ETFEFF, coupling efficiency of fat respiration; ETS, electron transport system; 
FCCP, carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; FT fibers, fast-twitch fibers; 
GE, gross efficiency; LCR, leak control ratio; LN, leak respiration without adenylates; LOmy, 
oligomycin-induced leak respiration; mATPase, myofibrillar adenosinetriphosphatase; MHC, 
myosin heavy-chain; MITEFF, mitochondrial coupling efficiency; OLD, old participants; P, 
oxidative phosphorylation capacity; PCI, respiratory capacity of complex I; PCII, respiratory 
capacity of complex II; PETF, fatty acid oxidative capacity; RER, respiratory exchange ratio; 
ROS, residual oxygen species; ROX, residual oxygen consumption; SOD2, mitochondrial 
superoxide dismutase 2; ST fibers, slow-twitch fibers; TBST, tris-buffered saline and 0.1 % 
Tween-20; O2peak, peak oxygen uptake; ww, wet weight; YNG, young participants. 
21 
 
Introduction 
Exercise efficiency (EE) is a measure of the whole body’s effectiveness in converting energy 
from nutrients into external work, i.e., the ratio of power output to the total metabolic energy 
cost (Gaesser and Brooks 1975). Whether EE is altered with aging is a matter of debate. 
Several studies have demonstrated an age-dependent increase in EE (Tevald et al. 2010; 
Venturelli and Richardson 2013; Venturelli et al. 2013), whereas others have not (Hopker et 
al. 2013; Sacchetti et al. 2010; Woo et al. 2006). One plausible explanation for the 
discrepancies between study outcomes could be fitness level since, generally, old individuals 
are suggested to be less trained than young persons (Amati et al. 2008; Gram et al. 2014; 
Russ and Kent-Braun 2004). This may introduce a bias as EE has been demonstrated to 
differ between trained and untrained individuals (Hopker et al. 2013) and may furthermore be 
improved with exercise training (Montero and Lundby 2015; Woo et al. 2006). Thus far, only 
Woo et al. (2006) and Hopker et al. (2013) included trained and untrained individuals of 
different age groups (20-33 and 50-77 yr); however, they did not match the groups according 
to peak oxygen uptake (V̇O2peak). Since V̇O2peak declines at a rate of approximately 4.0 mL 
kg−1 min−1 (8 %) per decade (Wilson and Tanaka 2000), this needs to be accounted for if 
young and old individuals are to be matched with regards to fitness level. Accordingly, one 
first aim of the present study was to assess EE in fitness-level-matched young (< 30 yr) and 
old (> 60 yr) individuals to test the hypothesis that EE is higher in the old population despite 
controlling for fitness level.  
Although individual variations in EE, irrespective of age, have been known to exist for 
decades (Gaesser and Brooks 1975), the underlying mechanisms remain elusive. Variations 
in EE are likely of multifactorial origin, including anatomical (Bramble and Lieberman 2004), 
biomechanical (Kyrolainen et al. 2000) and biochemical parameters (Mogensen et al. 2006) 
as well as muscle morphology (Coyle et al. 1992; Mogensen et al. 2006). Factors related to 
skeletal muscle morphology such as a high percentage of slow twitch (ST) fiber distribution 
have been correlated with a superior EE in some studies (Coyle et al. 1992; Mogensen et al. 
2006), but refuted in others (Hopker et al. 2013). With respect to age, preserved fiber type 
distribution or even a higher proportion of ST fibers and an increased area of ST fibers 
secondary to fast twitch (FT) fiber atrophy have been reported (Hopker et al. 2013). These 
findings are consistent with the observed denervation being a primary cause of myofiber 
atrophy at the myocyte level in the aging muscle (Rowan et al. 2012). A further aim of the 
present study was to determine the association between EE and skeletal muscle fiber type 
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distribution in old and young individuals to test the hypothesis that ST fiber distribution is 
higher in old individuals at similar fitness level and thus may explain the expected higher EE. 
Moreover, the reported association between skeletal muscle ST fibers and EE could be 
related to the often greater mitochondrial content in ST fibers compared to FT fibers 
(Jackman and Willis 1996). Thus, we also aimed to correlate citrate synthase (CS) activity, 
which has been suggested a suitable marker for mitochondrial content across individuals 
(Larsen et al. 2012b), to EE. Additionally, exercise has been reported to revert potential 
decreases in mitochondrial content with age (Broskey et al. 2013). We therefore 
hypothesized that a higher EE with age is associated with a higher distribution of ST fibers 
and, accordingly, higher mitochondrial content in the old compared to the young population 
when considering similar levels of fitness. Furthermore, Mogensen et al. (2006) assessed 
skeletal muscle mitochondrial efficiency in an attempt to explain differences in EE observed 
across young individuals, but did not find any correlation between these measures. Skeletal 
muscle mitochondrial function was however determined in isolated mitochondria and 
expressed per CS activity (Mogensen et al. 2006), and regrettably mitochondrial isolation 
disrupts the complex structural network and may thereby alter innate mitochondrial 
characteristics (Picard et al. 2010). Moreover, functional impairment of mitochondria with 
aging is exaggerated in isolated compared to permeabilized muscle fibers (Picard et al. 
2010). In contrast to the isolation procedure, permeabilization of myofiber bundles preserves 
mitochondrial morphology and integrity and hence allows to investigate the intact 
mitochondrial network. Unaltered mitochondrial function with age has been verified in 
permeabilized fibers (Gram et al. 2014; Larsen et al. 2012a). However, in one of these 
studies (Larsen et al. 2012a), the old and young individuals had similar O2peak, wherefore it 
cannot be definitely ruled out if the observed similar mitochondrial function was the result of a 
relatively better trained old population (Jacobs et al. 2013). Thus, another aim of this study 
was to test whether mitochondrial function assessed in permeabilized muscle fibers is 
comparable in old and young individuals at the same relative level of fitness. According to the 
findings of Gram et al. (2014), we hypothesized that mitochondrial function is preserved with 
age when controlling for fitness level and that a higher content of similarly functioning 
mitochondria leads to higher EE in old compared to young individuals.  
In summary, the purpose of the present study was to investigate whether EE is higher in old 
compared to young fitness-level-matched men and simultaneously to elucidate the potential 
source for the difference.  
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Methods 
Ethical approval 
The present experimental protocols were approved by the Ethical Committee of the ETH 
Zurich (ETH, EK 2011-N-24) and the Cantonal Ethics Committee of Zurich (2013-0114) and 
were conducted in accordance with the 1964 Declaration of Helsinki and its later 
amendments or comparable ethical standards. Participants were fully informed about the 
purposes, benefits and risks associated with this study and gave their written informed 
consent prior to the initiation of the experiments. 
Participants 
A total of 23 male individuals, 11 young (27 ± 4 yr, YNG) and 12 old (66 ± 4 yr, OLD) 
voluntarily participated in this study. Participants’ characteristics are presented in Table 1. All 
participants were recreationally active; they were neither sedentary nor highly trained. Apart 
from three OLD individuals with medically-controlled hypertension, all other participants were 
healthy and none had coronary heart disease, peripheral vascular disease, or clinically 
significant hyperlipidemia. When applicable, study participants answered specific health 
questions and provided a medical certificate of health. YNG and OLD were recruited for two 
separate exercise intervention studies, wherefrom one subset of data has already been 
published previously (Jacobs et al. 2013). All data published here have been separately 
analyzed for this study.  
Experimental design 
The experiments consisted of a skeletal muscle biopsy obtained from the m. vastus lateralis, 
a scan for body composition and an incremental exercise test to assess V̇O2peak. All 
experiments were conducted on separate days. 
Body composition measurement 
A densitometer (Lunar iDXATM, GE Healthcare, Madison, WI, USA) was used for the 
determination of total and lean soft tissue mass of the leg (legtotal, leglean) by performing dual-
energy X-ray absorptiometry (DXA) measurements.  
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Exercise testing 
Each participant conducted an incremental exercise test on an electrically braked cycle 
ergometer until voluntary exhaustion (YNG: Monark E839, Varberg, Sweden; OLD: 
Ergoselect 200K, Ergoline, Bitz, Germany) to determine V̇O2peak and EE. Pulmonary gas 
exchange and ventilation were continuously recorded using an online gas collection system 
(Innocor™ M400, Innovision, Odense, Denmark), where O2 and CO2 concentration were 
continuously measured and monitored as breath-by-breath values. The gas analysers and 
the flowmeter of the applied spirometer were calibrated prior to each test according to the 
manufacturer’s instructions. Protocols of the incremental tests differed between YNG and 
OLD, as the OLD were expected not to reach as high power outputs as the YNG. Therefore, 
the OLD started exercise at 0 W and power was increased by 20 W every 120 s until 
volitional fatigue. The YNG began with three consecutive submaximal 5-min power stages, 
starting at 50 W which was then increased to 100 and 150 W. Thereafter, workoad was 
increased by 30 W every 90 s until voluntary exhaustion. Pedal cadences were freely chosen 
by the participants but had to remain constant throughout the test and lay between 60 and 90 
rpm in YNG and OLD. V̇O2peak was determined as the highest mean over a 10-s period. With 
the intent to reduce the confounding factor of fitness level, V̇O2peak of the OLD were adjusted 
for age by adding 4 mL kg−1 min−1 per decade (Wilson and Tanaka 2000) and subsequently 
matched to the YNG. Consequently, fitness levels were determined as V̇O2peak which were 
adjusted for age according to the decreases in maximal heart rate with age (Wilson and 
Tanaka 2000). 
Exercise efficiency (EE) 
Calculations of EE from the incremental exercise tests were based on indirect calorimetry 
and the assumption that energy requirements were met by respiration. Gross efficiency (GE), 
delta efficiency (DE) and exercise economy (EC) were determined from V̇O2 of submaximal 
power values. GE was calculated using absolute (100 W, GE100) and relative (GErel) exercise 
intensities. For the calculation of GErel and DE, V̇O2 was averaged over the last 30 s at 
approximately 50 %, 60 % and 70 % V̇O2peak. The according power stages (YNG vs. OLD: 50 
%: 77 ± 34 vs. 63 ± 12 W; 60 %: 116 ± 29 vs. 88 ± 18 W; 70 %: 135 ± 38 vs. 107 ± 21 W) 
and V̇CO2 (mean over last 30 s) were extracted from the incremental exercise test (on the 
basis of Coyle et al. 1992). GE100 and GErel were calculated as the ratio of work 
accomplished to energy expended (Coyle et al. 1992; Gaesser and Brooks 1975). GErel was 
finally determined as the mean of all three submaximal power stages. To eliminate the 
influence of the basal metabolic rate (BMR) on energy expenditure, DE was calculated as the 
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ratio of change in work accomplished to change in energy expenditure (Coyle et al. 1992). 
For each subject DE was estimated from the reciprocal of the slope of the linear trend line of 
the relationship between energy expenditure and work accomplished (Coyle et al. 1992). To 
determine EC, V̇O2 was determined as the mean from 60 - 120 s at 100 W to obtain a 
steady-state value. EC was calculated for each subject by dividing power (100 W) by the 
according V̇O2 (Moseley and Jeukendrup 2001). The respiratory exchange ratios (RER) for 
submaximal power values were also calculated as the mean from 60 - 120 s at 100 W 
(RER100) and the mean from the ventilation and power stages according to 50 %, 60 % and 
70 % V̇O2peak (RERrel). 
Skeletal muscle sampling 
Skeletal muscle biopsies were obtained under standardized conditions from the m. vastus 
lateralis under local anesthesia (1 % lidocaine) of the skin and superficial muscle fascia, 
using the Bergström technique with a needle modified for suction. The biopsy was 
immediately dissected macroscopically free of fat and connective tissue and divided into 
sections for measurements of mitochondrial respiration, CS activity and oxidative stress as 
well as muscular fiber distribution. The part of the biopsy for the determination of 
mitochondrial respiratory capacity was immediately placed in ice-cold biopsy preservation 
solution. The samples for measurements of CS activity and oxidative stress were frozen in 
liquid nitrogen and stored at −80 °C until analyzed. Tissue for the determination of muscle 
fiber type distribution was instantly mounted in an embedding medium (Tissue-Tek®, Sakura, 
Zoeterwoude, The Netherlands), snap frozen in isopentane cooled to −160 °C with liquid 
nitrogen, and subsequently stored at −80 °C until use.  
Skeletal muscle fiber typing 
Consecutive 8 µm sections were cut on a microtome at −25 °C and mounted on glass cover 
slides for further histochemical analyses. The serial cryocut-cross-sections were stained 
using the myofibrillar adenosinetriphosphatase (mATPase) method after acid (pH 4.6) and 
alkali (pH 10.5) preincubation according to Item et al. (2011). For all analyses, only fibers 
fully encircled by adjacent fibers were evaluated using Adobe Photoshop Pro CS6 (Adobe 
Systems Incorporated, San Jose, CA, USA) and 812 ± 364 muscle fibers in YNG and 227 ± 
170 in OLD, respectively, were classified into ST and FT fibers. Fiber cross-sectional area 
(CSA) was determined by encircling the boundaries of the muscle cells of at least 50 fibers 
per fiber type. Only fibers with a cicularity higher than 0.7 were considered for analysis 
(perfect circle = 1.0).  
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Mitochondrial respiration measurement 
Samples were prepared as described in detail previously (Jacobs et al. 2012). In short, after 
mechanical fiber separation, chemical permeabilization in biopsy preservation solution and 
washing in mitochondrial respiration medium 05, respectively, muscle bundles were blotted 
dry and measured for wet weight (ww) in a balance-controlled scale (XS205 DualRange 
Analytical Balance, Mettler-Toledo AG, Greifensee, Switzerland). Respiration measurements 
were then performed in mitochondrial respiration medium 06. Oxygen consumption of the 
individual muscle tissue was measured at 37 °C using the high-resolution Oxygraph-2k 
(Oroboros, Innsbruck, Austria) with the titration of each substrate, uncoupler and inhibitor in 
series. Standardized instrumental and chemical calibrations were performed as 
recommended by the manufacturer and described previously (Jacobs et al. 2012). Oxygen 
flux was automatically calculated by the software, accounting for nonlinear changes in the 
negative time derivative of the oxygen concentration signal (DatLab, Oroboros, Innsbruck, 
Austria). All experiments were accomplished as duplicates in a hyperoxygenated 
environment to prevent any potential oxygen diffusion limitation. Oxygen concentration within 
the chambers ranged between 200 and 450 nmol mL−1.  
Respiratory titration protocol  
The applied protocol was specific to the analysis of individual aspects of respiratory capacity 
and coupling control efficiency during several substrate states induced via separate titrations. 
All titrations were added in series as presented, whereby the concentrations of substrates, 
uncouplers and inhibitors used were based on prior experiments (Jacobs et al. 2012). This 
titration protocol was modified from previous protocols where they are described in detail 
(Jacobs et al. 2012). Leak respiration in absence of adenylates (LN) was induced with the 
addition of octanoyl carnitine (0.2 mM) and malate (2 mM). The LN state represents the 
resting oxygen consumption of an unaltered and intact electron transport system (ETS) free 
of adenylates. Maximal electron flow through electron-transferring flavoprotein and maximal 
fatty acid oxidative capacity (PETF) was determined following the addition of ADP (5 mM). 
Submaximal state 3 respiratory capacity representative of electron capacity through complex 
I (PCI) was induced following the additions of pyruvate (5 mM) and glutamate (10 mM). 
Maximal state 3 respiration, oxidative phosphorylation capacity (P), was then induced with 
the addition of succinate (10 mM). P represents respiration that is resultant to saturating 
concentrations of ADP and substrate supply both for complex I and II. As an internal control 
for the integrity of the mitochondrial preparation, the mitochondrial outer membrane was 
assessed with the addition of cytochrome C (10 µM). Titration of oligomycin (1 µM) inhibited 
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ATP synthase and lead to oligomycin-induced leak respiration (LOmy). LOmy represents the 
corresponding leak state to P. In LOmy the chemiosmotic gradient is at maximum because of 
maximal substrate supply and inhibition of ATP synthase. Moreover, oxygen flux is at 
minimum and is representative of proton leak, slip, cation cycling and overall dyscoupling. 
Phosphorylative restraint of electron transport was assessed by uncoupling ATP synthase 
from the electron transport chain with the step-wise titration (4 x 0.5 µM) of the proton 
ionophore carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP), reaching ETS 
capacity (E). Rotenone (0.5 µM) was added to inhibit CI and to thereby assess electron flow 
specific to complex II (PCII). PCII is not influenced by the preceding addition of FCCP, which 
was verified with separate protocols in our laboratory. The addition of antimycin A (2.5 µM) 
that inhibits complex III allows the determination and correction of residual oxygen 
consumption (ROX), which is indicative of non-mitochondrial oxygen consumption in the 
chamber. Respiration measurements were terminated by simultaneous titration of ascorbate 
and TMPD to assess complex IV (COX) activity. TMPD and ascorbate are redox substrates 
that donate electrons directly to COX. Correction of O2 flux for the side reaction of auto-
oxidation was conducted by chemical calibration experiments prior to the measurements. 
Finally, mitochondrial leak control ratios (LCR) were analyzed as well. LCR are produced 
between two respiratory states, a leak state (low respiration) to a higher respiratory state. 
The corresponding states are paired by an identical substrate supply. The reference state is 
defined by the leak state. LCR allow the description of mitochondrial coupling efficiency, with 
a theoretical minimum of 0.0, indicating a fully coupled system, to a value of 1.0, 
representing a fully uncoupled system (Gnaiger 2009; Jacobs et al. 2012). Accordingly, LCR 
of LOmy to E is indicative of coupling efficiency across the entire respiratory chain and 
representative of mitochondrial coupling efficiency (MitEFF). Similarly, LCR of LN to PETF 
represents the coupling efficiency of fat respiration (ETFEFF).   
Homogenization 
Muscle samples were weighed (XS205 DualRange Analytical Balance; Mettler-Toledo AG, 
Greifensee, Switzerland) and put into cryotubes with ceramic beads (hard tissue 
homogenizing CK28, 2 mL, Precellys, Bertin Technologies, Montigny-le-Bretonneux, France) 
containing fresh MG-buffer (1:80, 1 mg of biopsy to 80 µL of buffer). MG-buffer was 
comprised of the following: 10 % glycerol, 20 mM sodium-pyrophosphate, 150 mM NaCl, 50 
mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES, pH 7.5), 1 % NP-40, 20 
mM β-glycerophosphate, 2 mM Na3VO4, 10 mM Na-F, 2 mM phenylmethanesulfonyl fluoride 
(PMSF), 1 mM ethylenediaminetetraacetic acid (EDTA, pH 8.0), 1 mM ethylene glycol-bis(2-
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aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA, pH 8.0), 10 µg mL−1 apoprotinin, 10 µg 
mL−1 leupeptin, 3 mM benzamidine. Samples were homogenized for 2 x 20 s at 6500 rpm 
with a 5 s pause (Precellys®24, Bertin Technologies, Montigny-le-Bretonneux, France). 
Thereafter, samples were turned end over end for 1 h at 4 °C, centrifuged at 16500 rpm for 
30 min at 4 °C and the supernatant (lysate) was aliquoted out and used for further analysis. 
Total protein concentration in each sample was determined using a bovine serum albumin 
(BSA) standard kit (Pierce, Rockford, IL, USA).   
Citrate Synthase (CS) activity  
CS activity was quantified fluorometrically at 412 nm and 25 °C according to the 
manufacturer (CS assay kit, Sigma-Aldrich, St. Louis, MO, USA) and as previously described 
(Jacobs et al. 2012). 
Immunoblotting of antioxidant enzymes 
Abundance of catalase and mitochondrial superoxide dismutase 2 (SOD2) was determined 
in the homogenized samples. Homogenates were solubilized in 4 x sample buffer containing 
4 x Laemmli sample buffer (161-0747, Bio-Rad, Hercules, CA, USA) and β-mercaptoethanol 
(161-0710, Bio-Rad, Hercules, CA, USA) and heated up to 95 °C for 5 min. Protein (15 µg 
per well) was added on 12.5 % precast polyacrylamide gels (12.5 % Criterion™ Tris-HCl Gel, 
345-0016, Bio-Rad, Hercules, CA, USA) and separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE, 10 x premixed electrophoresis buffer, 
containing 25 mM Tris, 192 mM glycine, 0.1 % SDS, pH 8.3, Bio-Rad, Hercules, CA, USA). 
The separated polypeptides were transferred to a PVDF membrane by the use of Trans-Blot 
Turbo Transfer System (Bio-Rad, Hercules, CA, USA) and blocked in tris-buffered saline and 
0.1 % Tween-20 (TBST) with 5 % non-fat milk. Membranes were cut and incubated overnight 
with rabbit polyclonal antibodies against catalase (ab16731, Abcam, Cambridge, MA, USA) 
and SOD2 (ab13534, Abcam, Cambridge, MA, USA) at a dilution of 1:1000. Anti-GAPDH 
was used as a loading control (ab9484, Abcam, Cambridge, MA, USA). After washing 3 x 10 
min with TBST, membranes were incubated with the appropriate anti-rabbit IgG (W4011, 
Promega, Madison, WI, USA) or anti-mouse IgG (W4021, Promega, Madison, WI, USA) 
horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. 
The membranes were again washed and incubated for 5 min each with a 
chemiluminescence detection marker (Luminata Classico Western HRP Substrate, 
WBLUC0100, Merck Millipore, Darmstadt, Germany) and detected by Fujifilm Image 
Analyser LAS-4000 (GE Healthcare, Buckinghamshire, United Kingdom). Relative intensities 
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of the protein bands were digitally quantified by using ImageJ (NIH, Bethesda, MD, USA) and 
normalized to GAPDH.  
Marker of oxidative stress  
Protein carbonyl groups represent one possible biomarker of oxidative stress (Dalle-Donne 
et al. 2003). Total protein carbonyl content in muscle lysates was determined according to 
the manufacturer’s recommendations using a commercially available kit (STA-308, OxiSelect 
Protein Carbonyl Immunoblot Kit, Cell Biolabs, San Diego, CA, USA). Values were 
expressed in arbitrary units (AU) and normalized to mg protein content.   
Statistics 
All data are presented as mean ± SD in text and figures. For all statistical evaluations, a 
value of P < 0.05 was considered significant. The statistical analysis was conducted using 
the software SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). Three different statistical 
models were used for analysis. After verifying normal distribution of the data, unpaired 
samples t-tests were used to test the null hypothesis stating no difference between YNG and 
OLD for GErel, GE100, DE, EC, RERrel, RER100, % ST and % FT fibers, CSA of ST and FT 
fibers, CS activity, MitEFF, ETFEFF, mass-specific and mitochondrial-specific (normalized to CS 
activity) respiratory capacities as well as for oxidative stress and antioxidant enzyme activity. 
Pearson’s Correlation Coefficients were calculated to test any relation between GErel and DE, 
respectively, and the according variables. If appropriate conditions were satisfied and there 
was no difference between groups, an analysis of covariance was conducted to measure the 
associations between GErel and % ST, % FT, CSA of ST and FT fibers, CS activity, P, MitEFF, 
ETFEFF (mass- and mitochondrial-specific), legtotal and leglean among the two age groups. 
These relations were only conducted for GErel, as GE reflects the efficiency of the entire 
human body in action and does not exclude BMR (Ettema and Loras 2009) and we 
considered the relative calculation to be more significant when comparing age differences.  
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Results 
All participants completed the skeletal muscle biopsy procedure, the DXA measurement and 
the incremental cycling exercise test. There was no difference in age-adjusted V̇O2peak 
between groups (Table 1), indicating appropriate matching of OLD and YNG participants 
according to fitness level.   
Exercise efficiency and age  
EE was assessed by the use of three different parameters: GE, DE and EC. Beyond, GE 
was calculated at absolute (GE100) and relative (GErel) exercise intensities (Table 1). 
Correlations between EE and other variables were only calculated for GErel as previously 
explained. GErel, GE100 and EC were 18, 25 and 29 % higher (P < 0.01) in OLD compared to 
YNG, whereas DE was not different (P = 0.149). RERrel and RER100 were lower in OLD (P < 
0.01).  
Lean mass and fiber type distribution  
There was no difference in legtotal, leglean (P = 0.457, P = 0.118, respectively) or in muscle 
fiber type distribution (P = 0.109) between the two groups (Table 1). CSA of FT fibers tended 
to be lower (P = 0.052) in OLD whereas CSA of ST fibers did not differ (Table 2). There was 
no correlation between CSA of ST or FT fibers, respectively, and GErel when data were 
pooled (r = −0.228; P = 0.295; r = −0.195; P = 0.374). Moreover, there was no overall 
correlation between GErel and legtotal (r = −0.153, P = 0.487), leglean (r = −0.203, P = 0.352), % 
ST (r = 0.104, P = 0.636) and % FT (r = −0.104, P = 0.637). Neither legtotal nor leglean had an 
influence on the higher GErel with age (P = 0.754; P = 0.976). Similarly fiber type distribution 
and CSA of ST or FT fibers, respectively, did not have any  influence on  GErel (P = 0.564; P 
= 0.310; P = 0.084).  
Skeletal muscle mitochondrial function and CS activity  
PETF (mass-specific respiration) was 56 % higher (P < 0.001) and PETF/CS (mitochondrial-
specific) was 38 % higher (P < 0.01) in OLD (Fig.1). In contrast, PCII and PCII/CS were 20 and 
36 % lower (P < 0.01) in OLD (Fig.1). All other respiratory states were similar in OLD and 
YNG; also MitEFF and ETFEFF did not differ (P = 0.571 and P = 0.230, respectively) between 
groups (Table 2). Furthermore, CS activity was not different between the two groups (P = 
0.098, Table 2), suggesting similar mitochondrial content. Pooled PETF (r = 0.559, P < 0.01) 
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and PETF/CS (r = 0.701, P < 0.001, Fig. 2) correlated with GErel, which could explain higher 
GErel in OLD. Contrary, GErel did not correlate with pooled P or P/CS (r = 0.108, P = 0.625; r 
= 0.142, P = 0.519). There was also no correlation between GErel and MitEFF or MitEFF/CS (r = 
0.211, P = 0.335; r = 0.189, P = 0.388), GErel and ETFEFF or ETFEFF/CS (r = −0.015, P = 
0.944; r = 0.063, P = 0.776) nor did GE and CS activity correlate (r = 0.022, P = 0.921) when 
the age difference was disregarded. DE did not correlate with any of the reported variables, 
except from ETFEFF and ETFEFF/CS, (r = 0.421, P < 0.05; r = 0.444, P < 0.05). Additionally, 
when the two age groups were considered, there was no correlation between GEREL and P or 
P/CS (P = 0.847; P = 0.073). Similarly, MitEFF and MitEFF/CS and ETFEFF and ETFEFF/CS, 
respectively, had no influence on the age-dependent increase in GEREL (P = 0.446 and P = 
0.110; P = 0.429 and P = 0.128). Lastly, also the similar CS activity did not have an influence 
on the higher GErel in OLD compared to YNG (P = 0.267). 
Oxidative stress and antioxidant enzyme activity  
There was no difference (P = 0.852) in catalase content between the two groups (Table 2). 
However, levels of SOD2 in OLD were higher (103 %, P < 0.01), suggesting an elevated 
level of antioxidant enzyme activity in OLD (Table 2). To indirectly determine the level of 
oxidative stress in skeletal muscle tissue, the content of carbonyl groups was determined 
(Table 2), which revealed higher oxidative stress in OLD (27 %, P < 0.05). 
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Fig. 1 (a) Mass-specific mitochondrial respiratory capacity and (b) mitochondrial-specific respiratory 
capacity (normalized to citrate synthase (CS) activity) in young (YNG, white bars) and old (OLD, black 
bars) participants. LN, leak respiration without adenylates; PETF, fatty acid oxidative capacity; PCI, 
respiratory capacity of complex I; P, oxidative phosphorylation capacity; LOmy, oligomycin-induced leak 
respiration; E, electron transport system capacity; PCII, respiratory capacity of complex II; ROX, 
residual oxygen consumption; COX, respiratory capacity of complex IV. Values are mean ± SD. *P < 
0.05; **P < 0.01; *** P < 0.001. nYNG = 11, nOLD = 12 
 
 
 
Fig. 2 Correlations irrespective of age (dotted line) between gross efficiency (GErel) and (a) mass-
specific maximal electron flow through electron-transferring flavoprotein (PETF, r = 0.559, P < 0.01) and 
(b) mitochondrial-specific maximal electron flow through electron-transferring flavoprotein (PETF/CS, r = 
0.701, P < 0.001). YNG, young participants; OLD, old participants. nYNG = 11, nOLD = 12
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Table 1 Characteristics of young (YNG) and old (OLD) participants 
 YNG OLD P-value 
age (yr) 27 ± 4 66 ± 4 < 0.001 
weight (kg) 80 ± 13 85 ± 14 0.450 
legtotal (kg) 28.3 ± 5.1 26.8 ± 4.7 0.457 
leglean (kg) 21.7 ± 3.7 19.4 ± 2.9 0.118 
Ppeak (W) 253 ± 50 184 ± 25 < 0.01 
absolute V̇O2peak (L min−1) 3.7 ± 0.6 2.5 ± 0.4 < 0.001 
relative V̇O2peak (mL min−1 kg−1) 46.7 ± 5.2 30.3 ± 4.3 < 0.001 
age-adj. V̇O2peak (mL min−1 kg−1) 46.7 ± 5.2 46.3 ± 4.3 0.875 
RERrel (-) 0.95 ± 0.07 0.80 ± 0.06 < 0.001 
RER100 (-) 0.99 ± 0.11 0.86 ± 0.08 < 0.01 
GErel (%) 14.0 ± 2.4 16.7 ± 1.5 < 0.01 
GE100 (%) 13.5 ± 1.7 17.4 ± 1.6 < 0.001 
DE (%) 22.1 ± 4.1 25.4 ± 6.3 0.149 
EC (kJ L−1) 2.7 ± 0.2 3.6 ± 0.4 < 0.001 
Values for YNG and OLD are represented as means ± SD, nYNG = 11, nOLD = 12. Legtotal, total mass of 
the leg; leglean, lean soft tissue mass of the leg; Ppeak, peak power; absolute V̇O2peak, absolute peak 
oxygen uptake; relative V̇O2peak, peak oxygen uptake per kg body weight; age-adj. V̇O2peak, age-
adjusted peak oxygen uptake per kg body weight; RERrel, respiratory exchange ratio at relative power 
stages; RER100, respiratory exchange ratio at 100 W; GErel, gross efficiency at relative power stages; 
GE100, gross efficiency at 100 W; DE, delta efficiency; EC, exercise economy 
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Table 2 Skeletal muscle properties in young (YNG) and old (OLD) participants 
 YNG OLD P-value 
CS (nmol mg−1 min−1) 144.8 ± 25.7 166.4 ± 33.3 0.098 
MitEFF (%) 32.9 ± 8.2 34.5 ± 4.1 0.571 
MitEFF/CS (%) 23.4 ± 7.0 21.6 ± 5.4 0.486 
ETFEFF (%) 34.8 ± 5.9 31.8 ± 5.9 0.230 
ETFEFF/CS (%) 25.1 ± 7.8 20.3 ± 6.7 0.129 
ST fibers (%) 53.4 ± 10.9 61.3 ± 11.7 0.109 
FT fibers (%) 46.6 ± 10.9 38.7 ± 11.7 0.109 
CSAST (µm2) 4945 ± 1402 4407 ± 1058 0.309 
CSAFT (µm2) 5246 ± 1383 4122 ± 1233 0.052 
Catalase (AU) 1.15 ± 0.97 1.08 ± 0.95 0.852 
SOD2 (AU) 0.64 ± 0.40 2.02 ± 1.33 < 0.01 
Protein carbonyl (AU) 0.09 ± 0.03 0.12 ± 0.02 < 0.05 
Values for YNG and OLD are represented as means ± SD, nYNG = 11, nOLD = 12. CS, citrate synthase; 
MitEFF, mitochondrial coupling efficiency; ETFEFF, coupling efficiency of fat respiration; ST fibers, slow-
twitch fibers; FT fibers, fast-twitch fibers; CSAST, cross-sectional are of slow-twitch fibers; CSAFT, 
cross-sectional area of fast-twitch fibers; SOD2, mitochondrial superoxide dismutase 2 
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Discussion 
This study demonstrates that EE is higher in OLD compared to YNG at similar levels of 
fitness. PETF was higher in OLD and positively correlated with EE. This higher lipid oxidative 
capacity with age was attended by lower RER at submaximal power in OLD. Moreover, DE 
was positively correlated with ETFEFF. Contrary to our hypothesis, fiber type distribution did 
not differ between groups and, hence, could not explain the higher EE in OLD. However, 
CSA of FT fibers tended to be lower in OLD which could indicate a higher reliance on the 
more efficient ST fibers with age. The present findings furthermore demonstrate that the 
higher EE in OLD is not related to CS activity, P, MitEFF, or ETFEFF, irrespective whether the 
age groups were pooled or not.  
Exercise efficiency and age  
In support of previous studies (Venturelli et al. 2013), the present findings demonstrate 
higher EE in older individuals, when GE and EC were used as measures for EE. Our findings 
extend previous work by considering the age-dependent decrease of V̇O2peak (Wilson and 
Tanaka 2000) when eliminating the confounding factor of fitness level. Contrary, Hopker et 
al. (2013) reported lower GE in trained old vs. trained young participants. However, 
considering GE at 100 and 150 W of their untrained old and untrained young participants, 
whose V̇O2peak (young ≈ 47 mL min−1 kg−1; old ≈ 34 mL min−1 kg−1) are in line with the present 
(YNG ≈ 47 mL min−1 kg−1; OLD ≈ 30 mL min−1 kg−1), a higher GE in the old untrained 
individuals becomes visible but was not statistically tested for (Table 2, Hopker et al. 2013). 
Since the relationship between caloric output and power has been reported to be linear or 
even slightly exponential, constant or decreasing EE with increasing power, respectively, 
have been implied (Gaesser and Brooks 1975). In general, the reported (Hopker et al. 2013) 
values for GE were slightly higher (100 W: young ≈ 16 % and old ≈ 17 %; 150 W: young ≈ 18 
% and old ≈ 19 %) than the values in the present study (YNG ≈ 14 % and OLD ≈ 17 %). This 
might be explained by the different calculation approach for GE, as we considered 
unmodified absolute and relative values (100 W and mean of 50, 60 and 70 % V̇O2peak, 
respectively) instead of absolute rescaled data (Hopker et al. 2013).  
Other studies have reported a decrease in EE with age during walking and running 
(Hortobagyi et al. 2011; Ortega and Farley 2007). However, as stated by the authors 
(Hortobagyi et al. 2011; Ortega and Farley 2007), the reported decrease in walking efficiency 
in old participants could likely be the consequence of the utilization of ancillary muscles and 
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may hence not be a result of muscular metabolic efficiency per se. Therefore the direct 
comparison between studies utilizing walking efficiency with those investigating cycling 
efficiency should be taken with some caution. Moreover, numerous studies did not control for 
activity or fitness level, which may further complicate a direct comparison (Russ and Kent-
Braun 2004). There are, however, findings demonstrating lower EE in well-trained old men 
during cycling (Sacchetti et al. 2010), which are contradictory to the present study. 
Discrepancies between studies could be due to biological differences such as anthropometric 
measures (Bramble and Lieberman 2004) but might also be explained by the training level of 
the participants, as they included highly trained cyclists (Sacchetti et al. 2010). The 
comparison of EE of Masters-level to younger elite cyclists could induce a bias since 
normative data from elite young cyclists should not be directly applied to evaluate the fitness 
level of the older (Peiffer et al. 2008). Additionally, cyclists have been reported to be able to 
increase their EE throughout their career (Coyle 2005). Nevertheless, it has been 
demonstrated that age-related changes in EE in untrained individuals can be reversed or 
enhanced with exercise training (Amati et al. 2008; Conley et al. 2013; Woo et al. 2006). 
Therefore, in support of our findings, cycling-specific EE can be preserved (Peiffer et al. 
2008) or even enhanced with age (Kent-Braun and Ng 2000; Lanza et al. 2005; Venturelli 
and Richardson 2013; Venturelli et al. 2013). 
To further solidify differences in EE with advances in age, we evaluated EE not only by 
considering absolute and relative GE but also DE and EC. DE, however, did not differ 
between YNG and OLD. A possible explanation for higher GE and EC but unchanged DE in 
OLD could be an age-dependent alteration in BMR. In contrast to GE, which reflects the 
efficiency of the entire human organism, and therefore also includes the influence of basal 
metabolism (Ettema and Loras 2009), DE is calculated by the change in energy expended 
relative to the change in actual work accomplished, whereby the influence of BMR is 
subtracted (Coyle et al. 1992; Gaesser and Brooks 1975). The validity of BMR subtraction, 
however, has been questioned (Ettema and Loras 2009; Moseley and Jeukendrup 2001) and 
GE and EC are both suggested more reliable measures of whole body efficiency than DE, 
which also displays a higher day-to-day variability (Ettema and Loras 2009; Moseley and 
Jeukendrup 2001). Accordingly, smaller changes in EE can be detected considering GE but 
not DE (Moseley and Jeukendrup 2001). Beyond, it seems unlikely that there was a 
difference in BMR between the two age groups, since on the one hand DE tended to be 
higher in OLD (25.4 ± 6.3 vs. 22.1 ± 4.1 %, P = 0.149) and on the other hand neither weight 
and lean body mass, which are among the main predictors of BMR (Cunningham 1980) nor 
legtotal and leglean differed between OLD and YNG.  
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Exercise efficiency and skeletal muscle fiber type distribution  
As EE has previously been shown to be related to the percentage of ST fibers in some 
studies (Coyle et al. 1992; Mogensen et al. 2006), we initially aimed to investigate whether 
this relationship was affected by training state and aging. However, skeletal muscle fiber type 
distribution was not related to GE and the higher GE in OLD did not correlate with fiber type 
distribution. These findings are in accordance with some studies (Amati et al. 2008; Hopker 
et al. 2013) but in contrast to others (Coyle et al. 1992; Mogensen et al. 2006). The 
discrepancy between the present findings and those who have reported a correlation 
between EE and skeletal muscle phenotype (Coyle et al. 1992; Mogensen et al. 2006) might 
be due to the fact that they included endurance trained cyclists and the percentage of ST 
fibers is related to the number of years of endurance training (Coyle et al. 1992). Thus, 
contrary to our hypothesis, fiber type distribution could not explain the observed difference in 
GE with age, irrespective if pooled or unpooled data were used. Moreover, fiber type 
distribution did not differ between the age groups, which is in agreement with previous 
findings (Hopker et al. 2013; Proctor et al. 1995; Purves-Smith et al. 2014). A possible 
explanation for the unchanged relative fiber type distribution with age could be the level of 
fitness of the included subjects. In support herefore legtotal and leglean did not differ between 
OLD and YNG, indicating an absence of age-dependent skeletal muscle atrophy if fitness 
level is taken into account. Others have also reported an unaltered skeletal muscle 
phenotype in sedentary (Coggan et al. 1992), recreationally active and trained (Proctor et al. 
1995) old. However, in the old, cross-sectional area occupied by ST fibers was higher than 
that occupied by FT fibers (Coggan et al. 1992; Proctor et al. 1995). The atrophy of FT fibers 
with age might again be explained by inactivity rather than aging per se (Coggan et al. 1992; 
Proctor et al. 1995). Alternatively, the decline in V̇O2peak with age (Wilson and Tanaka 2000) 
could limit absolute training intensity and thereby lead to atrophy of FT fibers, which in turn 
seems to be compensated for by increased ST area (Coggan et al. 1992). Hence, the 
physical activity level of the study participants could likely have contributed to the 
inconsistent findings regarding the direction and magnitude of changes in fiber type with age 
(Purves-Smith et al. 2014). Other possible explanations for the discrepant outcomes that 
may generate the hypothesis of an age-dependent shift in fiber type are reviewed in detail by 
Purves-Smith et al. (2014) and include: 1) the age of the participants. Most studies focus on 
the ages of 65 to 75 yr, which are ages not typically associated with mobility impairment and 
muscle atrophy; 2) different behaviour of different muscles with aging and a potential 
dependence of the shift in fiber type on its initial distribution; 3) the age-dependent increase 
in myosin heavy-chain (MHC) coexpressing fibers due to denervation (Rowan et al. 2012). 
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The present study reported no difference in CSA of ST fibers and only a tendency towards 
lower are of FT fibers with higher age. Since the OLD and YNG were compared at the same 
relative exercise intensity and muscle mass was similar, the OLD exercised at lower absolute 
power outputs, which may have facilitated a higher reliance on ST fibers in OLD compared to 
YNG, reflected by the tendency to lower area of FT fibers. Therefore, despite similar fiber 
type distribution a potentially higher recruitment of ST fibers could partly explain higher EE 
with advancing age.  
Exercise efficiency and mitochondrial function 
The activity of CS in the present study did not differ between the two groups. Thus, 
maintenance of CS activity with age indicates that mitochondrial enzyme activity and 
mitochondria populations are not affected by the aging process per se. This is in contrast to 
some studies that show a decline in CS activity with increasing age (Coggan et al. 1992; 
Conley et al. 2000). However, when fitness level was considered or controlled for, CS activity 
did not differ between old and young (Gram et al. 2014; Lanza et al. 2005; Larsen et al. 
2012a; Rasmussen et al. 2003), which is in line with our findings. In support, Broskey et al. 
(2013) demonstrated that aging does not affect mitochondrial biogenesis and that observed 
decreases in mitochondrial function with age are likely due to decreased physical activity. 
The unchanged CS activity suggests at least maintained skeletal muscle oxidative capacity 
and, if anything, CS activity tended to be even higher (P = 0.098) in OLD, which accords with 
the findings of Larsen et al. (2012a). The present findings, however, could not determine a 
positive association between GE and CS activity.  
In addition, we observed similar P and MitEFF in the two age groups. In support, also other 
investigators observed similar absolute maximum capacity of mitochondrial ATP synthesis 
between old and young study participants (Gram et al. 2014; Kent-Braun and Ng 2000). 
Similarly, maximal mitochondrial respiratory capacity in young (≈ 23 yr) and middle-aged (≈ 
53 yr) men at similar V̇O2peak did not differ, however, in contrast to our findings, mitochondrial 
respiratory capacity per mitochondrion was lower in the middle-aged (Larsen et al. 2012a). 
Yet, this discrepancy may be explained by the disregard of the age-related decline in V̇O2peak 
in the former study (Larsen et al. 2012a), as also others observed no difference in intrinsic 
mitochondrial capacity with age (Hutter et al. 2007; Lanza et al. 2005; Rasmussen et al. 
2003). In contrast, there are studies reporting reductions in mitochondrial respiratory capacity 
and oxidative capacity with age (Conley et al. 2000). However, none of these controlled for 
level of fitness, indicating that the results may rather be related to age-dependent lifestyle 
changes than to the aging process itself (Conley et al. 2013; Gram et al. 2014; Russ and 
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Kent-Braun 2004). Additionally, as discussed in detail by Rasmussen et al. (2003), the 
observed decline in mitochondrial function with age may also be likely due to heavy 
preparational damage. Collectively, by preserving muscle mass and function with age, 
mitochondrial biogenesis, morphology and function may remain stable. Accordingly, these 
data further suggest preserved mitochondrial respiratory function with age.  
Moreover, the present respirometry data suggest a higher capacity but not a higher efficiency 
of mitochondrial fat oxidation with age (higher PETF and PETF/CS in OLD vs. YNG), which may 
be reflected in the lower RER values of the OLD at submaximal work rates. These findings 
are confirmatory to the work of Amati et al. (2008) and Rimbert et al. (2004), who reported 
increased reliance on fat oxidation in old individuals during moderate-intensity exercise after 
exercise training (Amati et al. 2008) and unaltered fatty acid oxidative capacity with age 
(Rimbert et al. 2004), respectively. Noteworthy, we observed a positive relationship between 
GErel, PETF and PETF /CS activity and DE, ETFEFF and ETFEFF/CS, respectively. Hence, at least 
part of the increase in EE between OLD and YNG could be related to a higher capacity 
and/or efficiency for/of fatty acid oxidation and a maintained capacity for maximal 
mitochondrial respiration. Analysing the graph of this relation (Fig. 2), it should however be 
noted that this relation could be due to a stronger correlation between GErel and PETF of the 
YNG compared to the OLD. Nonetheless, Lanza et al. (2007) provided evidence of a higher 
metabolic economy in old vs. young human skeletal muscle in face of comparable 
mitochondrial respiratory capacity. This finding is in agreement with an age-dependent 
preferential reliance on oxidative phosphorylation, determined with magnetic resonance 
spectroscopy measurements (Lanza et al. 2007). The similar maximal capacity for 
mitochondrial ATP synthesis but higher preference for ATP production from oxidative 
phosphorylation (Lanza et al. 2007) together with the higher capacity for fat oxidation 
observed in the present study could be attributed to a higher ST recruitment (as previously 
discussed) and hence could account for an increase in EE. Contrary, there are findings 
indicating reduced fatty acid oxidation with age (Sial et al. 1996). However, fat oxidation rates 
at rest were similar in old and young individuals and higher in old at similar relative intensities 
(Sial et al. 1996), which reflects the design of the present study. Collectively, further 
investigations concerning metabolism, efficiency and the process of age are required. 
Oxidative stress and aging 
Augmented oxidative stress has been suggested to play an important role in the aging 
process, potentially leading to deficiencies in mitochondrial function. However, as discussed, 
we did not observe a decline in mitochondrial function. Furthermore, our data revealed higher 
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levels of SOD2 and carbonyl groups. The higher levels of antioxidant enzyme activity in OLD, 
represented by SOD2, may have been the result of a compensation for the larger number of 
carbonyl groups that represent a reliable marker for oxidative stress (Dalle-Donne et al. 
2003). Aged human muscle has been reported to show preserved mitochondrial function 
despite higher reactive oxygen species (ROS) production, estimated by dihydroethidium-
staining (Hutter et al. 2007). Collectively, the mechanisms for the higher levels of markers for 
oxidative stress despite maintained mitochondrial function remain to be further investigated.  
Limitations and outlook  
The present study bears the limits of a cross-sectional analysis, but was preferred over a 
longitudinal study due to time management. Another limitation could be the use of protocols 
with relatively short stage durations (120 s), which could have led to an overestimation of EE 
in the OLD as older adults demonstrate slower V̇O2 kinetics during non-steady-state 
conditions, implying greater EE than younger counterparts (Gravelle et al. 2012). Under 
steady-state conditions however, there were no changes in V̇O2 kinetics and hence no 
differences in EE between groups (Gravelle et al. 2012). Anyhow, slowing of V̇O2 kinetics in 
older individuals is to a large extent related to decreased physical activity and aerobic fitness 
with age (Berger et al. 2006; Grey et al. 2015). Moreover, moderately active older individuals 
reported similar V̇O2 kinetics to young counterparts (Chilibeck et al. 1998). Matching 
participants by fitness level and using the last 30 s for the calculation of energy expenditure 
should have enabled a valid determination of EE, which was randomly controlled. As pedal 
cadence was freely chosen between 60 and 90 rpm, this could also have limited the present 
results (Sacchetti et al. 2010). However, for this spectrum of cadences and considering the 
chance of choosing the convenient cadence, a major influence of pedal rate on EE in this 
study seems unlikely. For further improvements, also other factors could be considered in 
future studies: 1) Musculoskeletally less flexible distance runners tend to be more 
economical than more flexible runners, possibly because of the energy-efficient function of 
the elastic components in the muscles and tendons during the stretch-shortening cycle 
(Trehearn and Buresh 2009). Aging on the other hand has been associated with a decline in 
limb flexibility (Fukuchi et al. 2014), which may be an explanation for the increase in EE and 
which would be rather simple to assess; 2) Another aspect that could be investigated in 
future studies could be the potential age-related change in capillary morphology and its 
influence on EE, as capillary morphology may be related to whole-body V̇O2 kinetics.  
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Conclusions  
The present study extends previous studies in the field by accounting for the age-related 
decrease in V̇O2peak. Furthermore, EE was higher in OLD vs. YNG after controlling for % ST, 
% FT, CSA of ST and FT fibers, CS activity, P, MitEFF or ETFEFF. These finding indicate that 
impairments originally ascribed to age could be related to the negative effects of physical 
inactivity. Additionally, EE was positively correlated to PETF, suggesting that older individuals 
may have the possibility to rely more on fatty acid oxidation and are therefore more efficient. 
The higher capacity of fatty acid oxidation was further reflected by a lower RER with age. A 
potentially higher recruitment of ST fibers mirrored by a tendency towards lower FT fiber 
cross-sectional area could partly explain the higher reliance on fatty acid oxidation and 
thereby the higher EE with increasing age. The energetic needs of the older study 
participants were possibly met with a smaller perturbation of intracellular metabolism and 
may have therefore led to higher EE. Additional influencing factors on EE and the 
interdependency of age remain to be investigated, as EE is a key determinant of exercise 
capacity and thus mobility of the elderly. Increases in EE may have considerable implications 
for older individuals, who are at greater risk for functional impairments. Enhanced efficiency 
during physical activity would imply less energy requirements in the activities of daily living, 
which could be of clinical relevance.  
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Abstract 
Despite constant progress in the comprehension of biochemical and genetical characteristics 
in mitochondrial myopathy, the major pathomechanisms and therewith effective treatment 
approaches remain elusive. Therfore, the aim of the present study was to investigate 
disease-related impairments in skeletal muscle properties in mitochondrial myopathy. 
Accordingly, Skeletal muscle biopsies were obtained from six patients with 
moleculargenetically diagnosed mitochondrial myopathy (one male and five females, 53 ± 9 
y) and eight age- and gender-matched healthy controls (two males and six females, 58 ± 14 
y) to determine mitochondrial respiratory cacapcity of each single complex, mitochondrial 
volume density and fiber type distribution. Mitochondrial volume density (4.0 ± 0.5 vs. 5.1 ± 
0.8 %) as well as respiratory capacity of each individual complex were lower with 
mitochondrial myopathy (P < 0.05) and accompanied by a higher (P < 0.001) proportion of 
type II fibers (65.2 ± 3.6 vs. 44.3 ± 5.9 %). Additionally, mitochondrial volume density and 
maximal oxidative phosphorylation capacity positively correlated (P < 0.05) to peak oxygen 
uptake. In conclusion, mitochondrial myopathy leads to impaired mitochondrial quantity and 
quality and a shift towards more glycolytic skeletal muscle phenotype.  
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Introduction 
Mitochondrial cytopathies represent a heterogeneous group of progressive multisystem 
disorders with particular affection of the muscle and nervous system (Cohen and Gold, 2001; 
Schmiedel et al., 2003). Mitochondrial cytopathies are caused by mutations in either 
mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) encoding for mitochondrial proteins 
(Wallace, 1999; Tuppen et al., 2010). The irregular distribution of mitochondria in tissues, 
coexistence of mutated and wild-type mtDNA, so called heteroplasmy, and the widespread 
range of mutation lead to dysfunction in either one or several mitochondrial metabolic 
pathways including the respiratory chain and oxidative phosphorylation. These dysfunctions 
result in a clinical and genetic heterogenity, complexity and severity of symptoms that is 
characteristic for this syndrome (Di Mauro et al., 1985; Di Mauro, 2004; Schapira, 2006; 
Moggio et al., 2014). The functional consequence of defective oxidative phosphorylation 
particularly manifests itself in impaired energy production that amongst others affects skeletal 
muscle, a tissue with high-energy demand (Rossignol et al., 2000). The affection of skeletal 
muscle is defined as mitochondrial myopathy and represents a very common manifestation 
of mitochondrial cytopathies (Di Mauro, 2004), either isolated or combined with other 
symptoms of mitochondrial cytopathies. Although there has been constant progress in 
understanding the biochemistry and genetics of mitochondrial myopathy, many of the 
pathophysiological mechanisms remain unclear (Di Mauro, 2010). Not least due to the 
incomplete comprehension of these pathomechanisms, proven cures but also simple and 
effective diagnostic tools are lacking (Larsson and Oldfors, 2001; Di Mauro, 2004, 2010; 
Hassani et al., 2010; Tuppen et al., 2010). 
Patients with mitochondrial myopathy have been characterized by lower peak O2 uptake 
(V̇O2peak) and work capacity (Ppeak) in cycling exercise (Vissing et al., 1996; Taivassalo et al., 
2002; Taivassalo et al., 2003).  The limited whole body oxidative capacity in mitochondrial 
myopathy patients is likely caused by an impaired ability of the muscle to extract the 
available O2 from the blood, as it has been documented invasively by directly determining 
arteriovenous O2 difference (a-vO2 diff) across exercising muscles (Linderholm et al., 1969; 
Taivassalo et al., 2002) or indirectly (Vissing et al., 1996; Taivassalo et al., 2003) after the 
assessment of peak cardiac output (Q̇peak). The limited O2 extraction in turn may be explained 
by impaired oxidative capacity of the mitochondria itself and/or a reduced number of these 
organelles (Hoppeler et al., 1987) due to the disease-causing mutations or exercise 
intolerance. Exercise intolerance can be a prominent clinical manifestation of mitochondrial 
myopathy, leading to relatively low levels of exertion, fast fatigability and a sedentary lifestyle 
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(Taivassalo and Haller, 2005; Taivassalo et al., 2006). This sedentary lifestyle may further 
restrict the capacitiy of skeletal muscle for oxidative phosphorylation by the decrease in 
levels of functional mitochondria (Iqbal et al., 2013). Hence, it remains difficult to distinguish 
to what extent exercise intolerance is related to impaired mitochondrial oxidative capacity or 
associated with physical deconditioning due to a sedentary lifestyle. Assessments of muscle 
oxidative capacity and potential alterations with mitochondrial myopathy have previously 
been only conducted in case reports or small series (Taivassalo et al., 2003). Thereby, 
defects of the mitochondrial respiratory chain have been identified polarographically or by 
enzymatic assays (Morgan-Hughes et al., 1990; Rustin et al., 1994), usually involving 
complex I or III in adults and complex IV in children (Holt et al., 1989; Enns et al., 2005).  
Apart from the small series and lacking scientific controls, the poloarographic measurements, 
however, have been mainly conducted in complex combinations and not independently for 
each complex (Tarnopolsky and Raha, 2005). Moreover, these more global assessments of 
mitochondrial function were conducted in muscle homogenates or isolated fibers (Rustin et 
al., 1994). Mitochondrial isolation and homogenisation procedures however may disrupt the 
functional structural network and can thereby alter innate mitochondrial characteristics 
(Picard et al., 2010). Therefore, in vitro measurements of O2 consumption in permeabilized 
myofibers preserving innate mitochondrial function present a more promising approach to 
determine mitochondrial characteristics. Beyond, determination of the respiratory capacity of 
each individual complex could lead to a better understanding of mitochondrial function and 
potential mitochondrial-myopathy-related pathomechanisms. Additionally, detailed 
elucidation of potential pathomechanisms is important not only for the development of 
rational treatment options but also the initial diagnosis of mitochondrial myopathy. The 
absence of a consistent clinical phenotype has limited the viability of clinical identification and 
classification criteria of mitochondrial myopathy so far (Di Mauro, 2004; Tarnopolsky and 
Raha, 2005; Moggio et al., 2014). Thus, the primary aim of the present study was to 
determine mitochondrial volume densitiy and respiratory capacity of each individual complex 
in permeabilized muscle fibers of mitochondrial myopathy patients by implementing high-
resolution respirometry. Due to the ascertained moleculargenetic diagnosis of mitochondrial 
myopathy and the concomitant exercise intolerance, we hypothesized that mitochondrial 
volume density and respiratory capacity of each single complex in those patients would be 
decreased compared to age- and gender-matched healthy controls. Furthermore, this study 
aimed to test whether high-resolution respirometry measurements would represent a 
promising diagnostic tool leading to enhanced diagnostic and classification criteria of 
mitochondrial myopathy.   
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In addition, it has barely been investigated how muscle metabolism and morphology may be 
affected by mitochondrial dysfunction. Fiber type abnormalities including varying distribution 
of type I and II fibers as well as general or selective atrophy have been reported in patients 
with various mitochondrial respiratory chain dysfunctions (Gallanti et al., 1992; Muranaka et 
al., 1997; Enns et al., 2005) but not in adults with mitochondrial myopathy. One study 
including rats with modeled mitochondrial myopathy (Venhoff et al., 2012) directly assessed 
skeletal muscle fiber type adaptations in response to a primary defect of the mitochondrial 
respiratory chain and found a transformation from type I to type II fibers. Therefore, a further 
aim of the present study was to determine whether skeletal muscle morphology is affected in 
patients with mitochondrial myopathy. We hypothesized that skeletal muscle morphology is 
altered with mitochondrial myopathy leading to a shift towards more type II fibers.  
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Materials and methods 
Ethical approval 
The present experimental protocol was approved by the Cantonal Ethics Committee of 
Zurich (KEK 2012-0363) and was conducted in accordance with the Declarations of Helsinki. 
Participants were fully informed about the purposes, benefits and risks associated with this 
study and gave their written informed consent prior to the initiation of the experiments. 
Participants 
Six patients with mitochondrial myopathy (one male and five females, 53 ± 9 y), and eight 
age- and gender-matched healthy controls (two males and six female, 58 ± 14 yr), voluntarily 
participated in this study. Participants’ characteristics are presented in Table 2. Recruited 
patients (Table 1) were selected from a patient base followed at the neuromuscular research 
center (Department of Neurology, University Hospital Zurich, Switzerland) and matched by 
gender, age and as far as possible by physical activity patterns (assessed by interrogation) 
to healthy controls. In all patients biopsy findings (histochemical succinate dehydrogenase 
(SDH) staining technique together with electron microscopy and/or molecular genetic 
analysis of muscle mtDNA) were in accordance with the diagnosis of mitochondrial 
myopathy. Apart from manifested histological signs of myopathy and/or serum 
phosphocreatine kinase (CK) elevation, patients featured a history of muscle weakness, 
exercise intolerance or exercise-dependent myalgia (Table 1). Prior to any experiments, 
study participants were clinically examined and were screened to exclude potential 
pregnancy (urine sample) as well as any cardiac and/or respiratory disease. Several 
metabolic parameters including plasma lactate, glucose, insulin, leptin, glycated hemoglobin 
(HbA1c), thyroid stimulating hormone (TSH) and CK were measured prio to any study 
examinations and exercise. Cardiac and respiratory health was assessed by 24 h - 
electrocardiogram, cardiac ultrasound scan, spirometry tests and laboratory examination 
(lipid profile, glucose, precursorprotein brain natriuretic peptide (proBNP)). Patients and 
controls were neither completely sedentary nor highly trained and none of them exhibited 
diabetes, coronary heart disease, peripheral vascular disease or clinically significant 
hyperlipidemia.  
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Experimental design 
Clinical and exercise-physiological assessments were performed. Clinical assessments 
consisted of neurological examination, muscle strength examination, specific health 
questions (SF-36 Health Survey), Fatigue severity subscale of the Checklist Individual 
Strength (CIS-fatigue), recorded pain (visual analogue scale, VAS) and a skeletal muscle 
biopsy obtained from the vastus lateralis muscle. Exercise-physiological assessments 
included a scan for body composition, an incremental exercise test, a constant-load test and 
a knee extension torque measurement.  
Body composition measurement 
Total mass, bone mineral content (BMC), fat mass, percentage body fat, as well as total lean 
mass and lean soft tissue mass of the legs were determined by performing dual-energy X-ray 
absorptiometry (DXA) measurements using a densitometer (Lunar iDXATM, GE Healthcare, 
Madison, WI, USA).  
Exercise testing  
Each study participant conducted an incremental exercise test on an electrically braked cycle 
ergometer until volitional exhaustion (Ergoselect 200K, Ergoline, Bitz, Germany) to determine 
V̇O2peak and Ppeak. Additionally, all participants performed a constant-load test at 85 % Ppeak to 
establish time to exhaustion (tlim). Pulmonary gas exchange and ventilation were 
continuously recorded during both exercise tests using an online gas collection system 
(Innocor™ M400, Innovision, Odense, Denmark), where O2 and CO2 concentration were 
continuously measured and monitored as breath-by-breath values. The gas analysers and 
the flowmeter of the applied spirometer were calibrated prior to and after each test according 
to the manufacturer’s instructions. Throughout all cycling tests, heart rate was recorded 
(Polar S610i, Polar Electro, Kempele, Finland) and perceived exertion was interrogated by a 
Borgh Scale. In addition, blood pressure was registered on a regular basis during the 
incremental cycling test. The incremental cycling test consisted of a 3 min rest phase at 0 W, 
followed by exercise at 25 W with power increments of 25 W every 120 s until volitional 
fatigue. Pedal cadences were freely chosen by the participants but had to remain constant 
throughout the test and lay between 60 and 80 revolutions per minute (rpm). V̇O2peak was 
determined as the highest mean over a 10 s period. The respiratory exchange ratios (RER) 
for submaximal power values were absolutely calculated as the mean from 90 - 120 s at 25 
W (RER25W) and relatively as the mean over 10 s from the ventilation and power stages 
according to 50 % Ppeak (RERrel). The constant-load test included a 3 min rest phase at 0 W, 
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a 3 min warm-up of 1 min at 40 % and 2 min at 60 % that was followed by the constant 
power output according to 85 % Ppeak until volitional exhaustion.  
Isokinetic dynamometry 
Knee extensor maximal voluntary contraction torque (MVC) was assessed using an 
isokinetic dynamometer (Con-Trex MJ, Physiomed Elektromedizin, Schnaittach/Laipersdorf, 
Germany). Participants' bodies were stabilized with straps and handles according to the 
guidelines of the manufacturer. Each participant performed 3 maximal knee extensions (ω = 
3.14 rad s−1) separated by 1 min rest to assess MVC, whereby only the highest value out of 
the 3 trials was used for statistical analysis. 
Skeletal muscle sampling 
After a coagulation test, skeletal muscle biopsies were obtained under standardized 
conditions from the vastus lateralis muscle under local anesthesia (1 % lidocaine) of the skin 
and superficial muscle fascia, using the Bergström technique with a needle modified for 
suction. The biopsy was immediately dissected macroscopically free of fat and connective 
tissue and divided into sections for actual measurement of mitochondrial respiratory capacity, 
later transmission electron microscopy (TEM) and histochemistry. The part of the biopsy for 
the determination of mitochondrial respiratory capacity was directly placed in ice-cold biopsy 
preservation solution. For TEM, pieces of around 1 mm3 of each muscle biopsy were 
chemically fixed in 2.5 % glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3), stored at room 
temperature (RT) for 24 h and thereafter at 4 °C until all samples were collected. Muscle 
tissue for immunohistochemistry was instantly mounted in an embedding medium (Tissue-
Tek®, Sakura, Zoeterwoude, The Netherlands), snap frozen in isopentane cooled to −160 °C 
with liquid nitrogen, and subsequently stored at −80 °C until further processing.  
Mitochondrial respiration measurement 
Samples were prepared as described in detail previously (Jacobs et al., 2012). Summarised, 
after mechanical fiber separation, chemical permeabilization in biopsy preservation solution 
and washing in mitochondrial respiration medium 05, muscle bundles were blotted dry and 
measured for wet weight (ww) in a balance-controlled scale (XS205 DualRange Analytical 
Balance, Mettler-Toledo AG, Greifensee, Switzerland). Respiration measurements were 
subsequently performed in mitochondrial respiration medium 06. O2 consumption of the 
individual muscle tissue was thereby measured at 37 °C using the high-resolution Oxygraph-
2k (Oroboros, Innsbruck, Austria). Standardised instrumental and chemical calibrations were 
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performed as recommended by the manufacturer and described previously (Jacobs et al., 
2012). O2 flux was automatically calculated by the software, accounting for nonlinear 
changes in the negative time derivative of the O2 concentration signal (DatLab, Oroboros, 
Innsbruck, Austria). Experiments were performed as duplicates in a hyperoxygenated 
environment in order to prevent any potential O2 diffusion limitation. Thereby, O2 
concentration ranged between 200 and 450 nmol mL−1 within the chambers.  
Respiratory titration protocol 
The respiratory measurement protocol was specific to the analysis of individual aspects of 
respiratory capacity and coupling control efficiency during several substrate states induced 
via separate titrations. All titrations were added in series as presented, whereby the 
concentrations of substrates, uncouplers and inhibitors used were based on prior 
experiments (Jacobs et al., 2012). The titration protocol was modified from previous 
protocols where they are described in detail (Jacobs et al., 2012). In short, leak respiration in 
absence of adenylates (LN) was induced with the addition of octanoyl carnitine (0.2 mM) and 
malate (2 mM). Specifically, LN represents the resting O2 consumption of an unaltered and 
intact electron transport system (ETS) free of adenylates. Maximal electron flow through 
electron-transferring flavoprotein and maximal fatty acid oxidative capacity (PETF) was 
subsequently determined following the addition of ADP (5 mM). Electron capacity through 
complex I (PCI) was then induced following the additions of pyruvate (5 mM) and glutamate 
(10 mM). Maximal oxidative phosphorylation capacity (P) was induced with the addition of 
succinate (10 mM). P thereby represents respiration that is resultant to saturating 
concentrations of ADP and substrate supply both for complex I and II. As an internal control 
for the integrity of the mitochondrial preparation, the mitochondrial outer membrane was 
assessed with the addition of cytochrome C (10 µM). Following, ATP synthase was inhibited 
by the titration of oligomycin (1 µM) that lead to oligomycin-induced leak respiration (LOmy). 
LOmy represents the corresponding leak state to P. In LOmy the chemiosmotic gradient is at 
maximum because of maximal substrate supply and inhibition of complex V (ATP synthase). 
Additionally, O2 flux is at minimum and is representative of proton leak, slip, cation cycling 
and overall dyscoupling. By uncoupling ATP synthase from the electron transport chain with 
the step-wise titration (4 x 0.5 µM) of the proton ionophore carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone (FCCP) phosphorylative restraint of electron transport 
was assessed reaching ETS capacity (E). In order to inhibit CI and to assess electron flow 
specific to complex II (PCII) rotenone (0.5 µM) was added. PCII is thereby not influenced by the 
preceding addition of FCCP, which was verified with separate protocols in our laboratory. 
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The addition of antimycin A (2.5 µM) that inhibits complex III allows the determination and 
correction of residual O2 consumption (ROX), which is indicative of non-mitochondrial O2 
consumption in the chamber. Finally, respiration measurements were terminated by 
simultaneous titration of ascorbate and TMPD to assess complex IV (COX) activity. 
Ascorbate and TMPD represent redox substrates that donate electrons directly to COX. 
Correction of O2 flux for the side reaction of auto-oxidation was conducted by chemical 
calibration experiments prior to the measurements.  
Transmission electron microscopy 
The chemically fixed tissue was washed 3 x in 0.1. M cacodylate buffer and consecutively 
post-fixed in 1 % osmiumtetroxid in 0.1. M cacodylate buffer for 2 h at RT. After 3 x washing 
with milliQ H2O samples were block-stained with uranyl acetate (2 % in milliQ H2O) overnight 
at RT. The subsequent graded dehydration was conducted in a tissue processor (Leica EM 
TP, Leica Microsystems, Wetzlar, Germany) according to the following protocol: 10 min 70 % 
EtOH, 15 min 96 % EtOH, 4 x 30 min 100 % EtOH, 2 x 5 min and 2 x 10 min propylene 
oxide, 2 x 1 h 1:1 propylene oxide/Epon, 1 h 100 % Epon, 100 % Epon over night, 3 h Epon. 
Finally, samples were embedded in 100 % Epon in a non-oriented (isotropic) way and Epon 
was polymerized for 48 h at 60 °C. Ultrathin sections were cut on an ultramicrotome (Ultracut 
E ultramicrotome, Reichert, NY, USA) with a diamond knife (Diatome, Biel, Switzerland) and 
placed on 50 mesh hexagonal cupper grids (Plano GmbH, Wetzlar, Germany). Specifically, 
from each block three ultrathin sections (70 nm) were obtained at two depths separated by 
20 µm and placed onto two grids. Finally, the grids were contrasted with lead citrate 
(Reynolds, 1963). Micrographs were obtained in a FEI Tecnai G2 Spirit electron microscope 
(Tecnai G2 Spirit, FEI, Hillsboro, OR, USA) mounted with an Orius SC1000 charged-coupled 
device (CCD) camera (Gatan, Pleasanton, GA, USA) and interfaced with the TEM software 
(TEM User Interface, FEI, Hillsboro, OR, USA). Micrographs were acquired in a uniform 
random systematic order. For each grid three predetermined positions were marked for 
further imaging. At each position an area of 222 x 146 µm2 (pixel size of 57.7 nm) was used 
for automated image capturing by the TEM photomontage software. A random starting point 
was selected for the first micrograph whereafter further micrographs were taken at fixed x-, y-
intervals of 64 and 42 µm, respectively. Nine 15.9 x 10.5 µm2 micrographs (3840 x 2528 
pixels) were captured in each area. Consequently, for each biopsy a total of 54 micrographs 
were acquired (9 micrographs per 3 positions per 2 sections per sample). Subsequently, 
skeletal muscle volume density of mitochondria (MitoVD) was estimated by point counting in 
combination with Cavalieri's principle (West, 2012) using the Stereo-Investigator software 
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(MBF Bioscience, Williston, ND, USA). For point counting a grid spacing of 1 µm along bot x- 
and y-axis was applied. Each point was assigned as either intermyofibrillar (IMFVD) or 
subsarcolemmal (SSVD) mitochondrial volume density, lipid droplet volume density (LDVD), 
skeletal muscle or "nothing". SS mitochondria were defined as the mitochondria that were 
not separated by myofibrils from the sarcolemma.  
Histochemistry 
Consecutive transverse sections (8 µm) were cut at three depths on a microtome (Leica CM 
1850, Leica Biosystems, Wetzlar, Germany) at −22 °C, mounted on glass cover slides 
(Superfrost Plus, Thermo Fisher Scientific Inc., Rockford, IL, USA), set to air dry and stored 
at -20 °C until further processing. The serial sections were then fixed in 3 % neutral buffered 
formalin at RT for 45 min, briefly washed and blocked with 5 % goat serum. Thereafter, the 
sections were firstly incubated with a primary antibody against myosin heavy chain (MyHC) 
isoform I (Novocastra Lyophilized Mouse Monoclonal Antibody Myosin Heavy Chain (slow), 
NCL-MHCs, Leica Biosystems, Wetzlar, Germany) and secondly with goat anti-rabbit IgG 
secondary antibody conjugated with Alexa Fluor 488 (Thermo Fisher Scientific Inc., 
Rockford, IL, USA). The sarcolemma of the skeletal muscle fibers were visualized by 
incubation with a primary antibody against laminin (Novocastra Lyophilized Mouse 
Monoclonal Antibody Laminin, NCL-LAMININ, Leica Biosystems, Wetzlar, Germany) in 
combination with goat anti-rabbit IgG secondary antibody, Alexa Fluor 647 conjugate 
(Thermo Fisher Scientific Inc., Rockford, IL, USA). An automated upright microscope system 
was used for digitizing the sections (Leica, DM5500 B, Leica Microsystems, Wetzlar, 
Germany). Skeletal muscle fiber type distribution was determined according to their MyHC-I 
and MyHC-II isoforms and classified into type I and type II fibers. For all analyses, only fibers 
fully encircled by adjacent fibers were evaluated using Adobe Photoshop Pro CS6 (Adobe 
Systems Incorporated, San Jose, CA, USA). Fiber cross-sectional area (CSA) was 
determined by encircling the boundaries of the muscle cells of at least 50 fibers per fiber 
type. Only fibers with a circularity higher than 0.7 were considered for analysis (perfect circle 
= 1.0). 
Statistical analysis 
All data are presented as mean ± SD in text and figures. The statistical analysis was 
conducted using the software SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). After 
verification of normal distribution of the data, two-tailed unpaired samples t-tests were 
conducted to test the null hypothesis stating no difference between patients with 
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mitochondrial myopathy and health controls. For all statistical analyses, a value of P < 0.05 
was considered significant. Spearman’s rank correlation coeffiencts were calculated to 
determine potential dependences of several variables. The number of patients and controls 
included in each data set are always indicated and can vary due to inability of cycling above 
a power output of 0 W (1 case) or technical problems with the devices (2 cases).    
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Results 
All participants completed the skeletal muscle biopsy procedure and DXA measurement. 
Except from one patient who was not able to cycle against a certain resistance (25 W), all 
participants conducted the incremental and the constant-load cycling exercise test.  Due to 
technical reasons, one patient and one control could not perform the isokinetic dynamometry 
test. There was no difference in age or weight between groups (Table 2).   
Body composition  
Body composition did not differ between patients and controls in any of the tested 
parameters (Table 2).  
Oxygen kinetics 
V̇O2peak was 45 % lower (P < 0.05) in mitochondrial myopathy patients than in healthy 
controls, with a broad range in both groups (Table 2). In accordance, Ppeak was 53 % lower (P 
< 0.05) with mitochondrial myopathy. However, RER at the same absolute and relative power 
output did not differ between groups, suggesting similar metabolic regulations in patients and 
controls at submaximal work rates.  
Skeletal muscle mitochondrial volume density and respiratory capacity  
 Maximal mitochondrial respiration specific to each individual mitochondrial complex (mass-
specific respiration, respiration per mg ww) was lower (P < 0.05) in patients with 
mitochondrial myopathy vs. healthy controls (Figure 1A). In particular, difference in mass-
specific respiratory capacity with mitochondrial myopathy amounted to 50 (PCI), 46 (PCII), 45 
(P), 48 (COX) and 47 % (ETS). Additionally, MitoVD was on average 23 % lower (P < 0.05) in 
patients, which was related to the lower IMFVD (Table 3). Moreover, after normalizing 
mitochondrial respiratory capacity to MitoVD all respiratory states specific to the five 
mitochondrial complexes were lower (P < 0.05, Figure 1B) in patients (28 (PCI), 24 (PCII), 23 
(P), 28 (COX) and 24 % (ETS)), suggesting quantitative and qualitative alterations in 
mitochondrial function with mitochondrial myopathy. In contrast, LCR did not differ (P = 
0.501) between groups (mitochondrial myopathy 0.42 ± 0.07; controls 0.44 ± 0.05).  
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Skeletal muscle fiber type distribution 
Mitochondrial myopathy demonstrated a higher (P < 0.001) ratio of FT to ST fibers and a 
tendency (P = 0.070) towards lower CSA, indicating potential skeletal muscle atrophy (Table 
3). However, CSA specific to ST and FT fibers did not differ (P = 0.133; P = 0.127) between 
patients and controls (Table 3).  
Correlations 
The mutation load in the 6 patients ranged from 12 to 95 %. There was no relationship 
between percentage mutation and any of the other determined variables. V̇O2peak was 
positively correlated (P < 0.05) to P (ρ = 0.626), MitoVD (ρ = 0.577) and P normalized to 
MitoVD (ρ = 0.648). Moreover, P, MitoVD, P/MitoVD as well as lean mass were all related to 
CSA of ST fibers (ρ = 0.653, ρ = 0.600, ρ = 0.618, ρ = 0.578; P < 0.05).  
 
Fig. 1 Mass-specific mitochondrial (A) and  mitochondrial-specific (B) respiratory capacity (normalized 
to MitoVD) in patients with mitochondrial myopathy (white bars) and healthy controls (black bars). LN, 
leak respiration without adenylates; PETF, fatty acid oxidative capacity; PCI, respiratory capacity of 
complex I; P, oxidative phosphorylation capacity; LOmy, oligomycin-induced leak respiration; E, electron 
transport system capacity; PCII, respiratory capacity of complex II; ROX, residual oxygen consumption; 
COX, respiratory capacity of complex IV. Values are mean ± SD. *P < 0.05; **P < 0.01. nPatients = 6, 
nControls = 8 
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Table 1 Clinical and molecular characteristics of patients with mitochondrial myopathy  
patient sex 
 
age of 
onset 
(yr) 
diagnosis clinical features [CK]rest    
(U L−1) 
[L−]rest        
(mmol 
L−1) 
genetic 
defect 
mutant 
mtDNA 
(%) 
muscle biopsy 
1 f 20 CPEO ptosis, external 
ophthalmoplegia, facial 
weakness, slight 
general weakness 
219 normal 4977 
bp 
95 COX−, ragged 
blue fibers 
2 m 33 CPEO ptosis, external 
ophthalmoplegia, 
general weakness, 
exercise intolerance 
401 normal 4405 
bp 
90 unremarkable 
3 f 62 MM mild proximal lower 
extremities weakness 
normal normal 5-13 
kbp 
49-71 COX−, ragged 
blue fibers 
4 f 12 MM exercise induced 
myalgia 
206 normal 10-13 
kbp 
35 COX−, SDH+, 
ragged red 
fibers 
5 f  MM exercise induced 
myalgia 
normal normal 6-10 
kbp 
62 ragged red 
fibers 
6 f 39 MM exercise induced 
myalgia 
normal 5.3 8-12 
kbp 
12-36 unremarkable 
[CK]rest, blood creatine kinase concentration at rest; COX−, cytochrome oxidase negative fibers; 
CPEO, chronic progressive external ophthalmoplegia; [L−]rest, blood lactate concentration at rest; MM, 
mitochondrial myopathy; mtDNA, mitochondrial DNA; SDH+, succinate dehydrogenase positive fibers 
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Table 2 Physiological characteristics of patients with mitochondrial myopathy (n = 6) and healthy 
controls (n = 8) 
 patients controls P-value 
age (yr) 53 ± 9 58 ± 14 0.437 
weight (kg) 75 ± 18 67 ± 12 0.376 
height (cm) 162 ± 7 167 ±7 0.238 
BMC (kg) 2.33 ± 0.18 2.36 ± 0.43 0.867 
fat mass (kg) 23.1 ± 16.3 14.2 ± 11.6 0.255 
lean mass (kg) 38.4 ± 13.3  41.4 ± 13.9 0.683 
lean mass legs (kg) 19.3 ± 11.1  19.0 ± 8.8 0.951 
total body fat (%) 39 ± 13  31 ± 6 0.153 
relative V̇O2peak (mL min−1 kg−1) 19.8 ± 6.8a 32.6 ± 7.3 < 0.01 
Ppeak (W) 78 ± 21a 165 ± 60 < 0.05 
[L−]rest (mmol L−1) 1.64 ± 0.88 1.11 ± 0.62 0.207 
RER25W (-) 0.72 ± 0.06a 0.69 ± 0.06 0.447 
RERrel (-) 0.78 ± 0.08a 0.77 ± 0.05 0.923 
HRpeak(min−1) 144 ± 28a 158 ± 16 0.257 
tlim (s) 278 ± 154a 541 ± 321 0.118 
MVC (Nm) 54.3 ± 41.9a 80.6 ± 43.3b 0.278 
Values are represented as means ± SD. [L−]rest, blood lactate concentration at rest; BMC, bone mineral 
content; HRpeak, peak heart rate; MVC, maximum voluntary contraction; Ppeak, peak power; relative 
V̇O2peak, peak oxygen uptake per kg body weight; RER25W, respiratory exchange ratio at 25 W; RERrel, 
respiratory exchange ratio at 50% Ppeak; tlim, time to exhaustion. a n = 5; b n = 7 
63 
 
 
Table 3 Skeletal muscle properties of patients with mitochondrial myopathy (n = 6) and healthy 
controls (n = 8) 
 patients controls P-value 
Type I fibers (%) 34.8 ± 3.6  55.7 ± 5.9  < 0.001 
Type II fibers (%) 65.2 ± 3.6  44.3 ± 5.9 < 0.001 
CSA total (µm2)  3438 ± 915 4698 ± 1328  0.070 
CSA type I fibers (µm2)  3991 ± 1211 5234 ± 1566  0.133 
CSA type II fibers (µm2) 3178 ± 852 4359 ± 1592  0.127 
MitoVD (%) 4.0 ± 0.5 5.1 ± 0.8 < 0.05 
IMFVD (%) 3.4 ± 0.4  4.1 ± 0.5 < 0.05 
SSVD (%) 0.6 ± 0.3  1.0 ± 0.5 0.118 
LDVD (%) 0.4 ± 0.1  0.4 ± 0.3 0.660 
Values are represented as means ± SD. CSA, cross sectional area; IMFVD, intermyofibrillar 
mitochondrial volume density; LDVD, lipid droplet volume density; MitoVD, mitochondrial volume density; 
SSVD, subsarcolemmal mitochondrial volume density 
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Discussion 
The main finding of the present study is that skeletal muscle mitochondrial function in 
mitochondrial myopathy patients is lower than in healthy controls and that this is the result of 
a reduced mitochondrial volume density as well as diminished intrinsic mitochondrial 
function. Furthermore, patients exhibited a shift in skeletal muscle fiber type towards more 
type II fibers and tended to an atrophic muscle phenotype. Moreover, maximal O2 uptake and 
exercise performance in patients with mitochondrial myopathy were lower than in the 
included healthy controls. Mitochondrial volume density and maximal oxidative 
phosphorylation capacity were positively correlated to V̇O2peak. Thus, mitochondrial myopathy 
is associated with decreased mitochondrial quantity and quality and diminished the capacity 
for whole-body maximal O2 uptake.  
This is the first study determining skeletal muscle mitochondrial volume density and 
respiratory capacity of each single complex in permeabilized fibers from mitochondrial 
myopathy patients in comparison to age- and gender-matched healthy controls. Thereby, not 
only MitoVD but also the mass-specific (per mg ww) and mitochondrial-specific (normalized to 
MitoVD) respiratory capacity of each individual complex were affected by mitochondrial 
myopathy, indicating an evident impairment of innate mitochondrial function. Together, the 
lower mitochondrial quantity and quality may limit skeletal muscle’s ability to extract O2 from 
the blood (Hoppeler et al., 1987) and finally leading to an impaired maximal oxygen uptake 
capacity of the whole body. Particularly, the lower O2 extraction capacity of the skeletal 
muscle is likely to result in an exaggerated systemic O2 delivery relative to O2 utilization, i.e. 
a hyperkinetic circulation, causing typical symptoms of mitochondrial myopathy as metabolic 
acidosis, exertional dyspnea, exercise intolerance, low exercise performance and 
consecutively reduced quality of life (Linderholm et al., 1969; Vissing et al., 1996; Taivassalo 
et al., 2002; Taivassalo et al., 2003; Heinicke et al., 2011). Hence, the present bioenergetics 
impairments at the cell organelles’ level seem to result in abnormal cardiac and ventilatory 
responses to increased O2 requirements as in response to physical activity and exercise 
(Dandurand et al., 1995; Flaherty et al., 2001; Heinicke et al., 2011) and therewith to cause 
impaired exercise capacity in patients with mitochondrial myopathy. Noteworthy, exercise 
capacity in patients with mitochondrial myopathy was lower than in healthy matched controls 
and varied broadly, reflecting the heterogeneous clinical manifestation and severity of this 
disease. In addition, V̇O2peak correlated with measures of mitochondrial quantity and quality, 
indicating an association with reduced skeletal muscle O2 uptake capacity, which as been 
indicated by previous studies in our laboratory before (Jacobs et al., 2013; Jacobs and 
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Lundby, 2013). In support, since Q̇peak has been reported not to differ between mitochondrial 
myopathy and healthy controls (Taivassalo et al., 2003), diminished V̇O2peak may be 
explained by a lower systemic a-vO2 diff, which not at last represents a marker for 
mitochondrial oxidative phosphorylation capacity (Linderholm et al., 1969; Vissing et al., 
1996; Taivassalo et al., 2002; Taivassalo et al., 2003).   
To our knowledge, this is also the first study demonstrating a previously unreported skeletal 
muscle fiber type transformation from type I to type II fibers in adult patients with 
mitochondrial myopathy. This finding contrasts a histochemically described type I fiber 
predominance as a compensation for impaired energy production and mitochondrial function 
in children with mitochondrial myopathy (Enns et al., 2005). As type 1 fibers usually contain a 
higher proportion of mitochondria than type II fibers (Gouspillou et al., 2014), an enhanced 
ratio of type I to type II fibers could increase the number of mitochondria and lead to a 
potentially greater capacity for energy production (Enns et al., 2005). In turn, decreased 
oxidative capacity could also be compensated by a switch from an oxidative to a more 
glycolytic phenotype in order to partially restore muscle strength and energy production, yet 
leading to higher lactate production that is characteristic for this disease (Vissing et al., 1996; 
Jeppesen et al., 2003). Lactate in turn represents an important fuel for oxidative metabolism 
and has been reported to rather enhance energy production than inducing fatigue in patients 
with mitochondrial myopathy (Jeppesen et al., 2013). In support of our findings, Venhoff et al. 
(2012) reported a fiber type shift from type I to type II fibers in mitochondrial myopathy 
modeled rats which was paralleld by adjustments in metabolic profile. The lower MitoVD in 
patients with mitochondrial myopathy, which was related to lower IMFVD, may thereby reflect 
the decreased type I to type II fiber ratio. SSVD in the present study did not differ and only half 
of the mitochondrial myopathy patients demonstrated ragged-red fibers (RRF, Table 1). 
Together these findings, however, contrast previous reports of SS mitochondrial 
proliferations and simultaneously occurring RRF with mitochondrial myopathy (Di Mauro et 
al., 1985; Rollins et al., 2001; Enns et al., 2005). Moreover, mitochondrial myopathy modeled 
mice demonstrated RRF and increased skeletal muscle mitochondrial volume density, 
particularly in the SS region, wheras respiratory chain enzyme activities were decreased 
(Wredenberg et al., 2002). Therefore, the authors suggested the higher mitochondrial mass 
to partly compensate for the respiratory chain deficiency and the reduced mitochondrial ATP 
production being not as critical for the pathophysiology of mitochondrial myopathy as 
previously thought (Wredenberg et al., 2002). Accordingly, recent studies displayed altered 
Ca2+ handling in mitochondrial myopathy (Aydin et al., 2009; Gineste et al., 2015), stimulating 
the discussion of progressive muscle weakness rather than energy deficiency as potential 
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dominating pathomechanism (Gineste et al., 2015). Collectively, these partially divergent 
findings may once more reflect the heterogeneous character of this disease and the possible 
detrimental effect of physical inactivity in mitochondrial myopathy patients, which in turn 
emphasizes the need for further studies also on alternate pathophysiological mechanisms.  
Discriminating exercise intolerance caused by defective mitochondria and the mutation itself 
from that of disease associated inactivity and hence physicial deconditioning remains 
challenging. Exercise intolerance inevitably results in reduced levels of habitual physical 
activity and causes physical deconditioning that in turn leads to a vicious cycle of further 
deconditioning and progressive exercise intolerance (Taivassalo and Haller, 2004). In spite 
of matching patients and controls according to age, gender and, as far as possible, to 
reported physical activity levels, the lower V̇O2peak and Ppeak in patients with mitochondrial 
myopathy could be due to sustained physical inactivity associated with the disease-related 
exercise intolerance. Thereby, the present lower MitoVD and mitochondrial respiratory 
capacity in patients with mitochondrial myopathy could indeed also simply be a reflection of 
this vicious cycle. Disuse or physical inactivity, respectively, have been reported to lead to 
decreases in mitochondrial volume density and hence mitochondrial function (Gram et al., 
2014; Tryon, 2014). In line herewith is the lower IMFVD with mitochondrial myopathy, as IMF 
mitochondria represent a specialization towards energy production for contractile activity 
(Ferreira et al., 2010). Reduced contractile activity due to physical inactivity in patients with 
mitochondrial myopathy could have resulted in lower IMFVD and secondary impaired 
mitochondrial function. In support, muscle homogenates of mice with mitochondrial myopathy 
due to a COX deficiency exhibited increased mitochondrial mass, oxidative capacity and 
exercise performance after an endurance exercise training intervention in comparison to 
sedentary diseased mice (Wenz et al., 2009). However, although the enhanced physical 
activity led to a preservation of oxidative capacity of 50 – 60% of wild-type levels in 
comparison to the drop to 10 – 40 % in sedentary diseased mice in 3 month duration, 
oxidative capacity still remained reduced compared to wild-type controls. Moreover, 
mitochondrial COX activity was not affected by the exercise intervention (Wenz et al., 2009). 
The partially sustained oxidative capacity in muscle homogenates together with the 
persistent COX defect at the mitochondrial level in exercised diseased mice indicates only 
increased mitochondrial quantity but not quality with exercise (Wenz et al., 2009). Therefore, 
lower MitoVD but rather not impaired intrinsic mitochondrial function could be explained by 
physical inactivity due to exercise intolerance.  
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Congruently, two weeks of physical inactivity induced by one leg immobilization led to 
reduced mitochondrial respiratory capacity due to changes in mitochondrial content but not 
intrinsic mitochondrial function (Gram et al., 2014). In the present study, similar total lean 
mass and lean mass of the lower limbs in mitochondrial myopathy patients and healthy 
controls may suggest that the diminished mitochondrial volume density, function and 
exercise performance are possibly associated with the disease itself rather than with 
inactivity alone. Additionally, patients with mitochondrial myopathy exhibited comparable 
MVC and tlim as their healthy controls, which contradict different levels of physical activity. In 
support, mice with mitochondrial myopathy showed a decrease in ATP levels even with 
exercise, which was less than in sedentary diseased mice but dropped to 30% of wild-type 
after 10 month (Wenz et al., 2009). Considering the shift towards more type II fibers and the 
trend to general fiber atrophy, physical inactivity should still be considered as a potential 
cause. However, muscle disuse affects mainly type I fiber diameter (Booth and Gollnick, 
1983; Zhong et al., 2005), which did not differ between patients and controls. This is further 
supported by a rat model of mitochondrial myopathy, reporting a predominate type II fiber 
atrophy (Venhoff et al., 2012). Interestingly, with chronic obstructive pulmonary disease 
(COPD) muscle hypoxia is, as the case with mitochondrial myopathy, associated with an 
increased proportion of type II fibers (Hildebrand et al., 1991), a reduced number of 
mitochondria (Gosker et al., 2007), increased glycolytic enzyme activity and an impaird 
oxidative capacity (Howald et al., 1990). Conclusively, mechanism related to mitochondrial 
dysfunction and the disease-causing mutations itself could have induced the present 
pathologic findings. However, physical inactivity could secondarily have led to further 
aggraviation of decreased exercise capacity and mitochondrial function. Therefore, the 
present study cannot clarify whether  the findings are only related to the disease per se or in 
addition to inacitivity.  
From a clinical point of view, the diagnosis of mitochondrial cytopathies or mitochondrial 
myopathy, respectively, remains challenging and requires the combined application of 
multiple methodologies (Milone and Wong, 2013). Blood samples may exhibit increased 
resting lactate concentrations and elevated CK levels. However, lactic acidosis is often not 
present and CK levels may be normal or only mildly increased. Functional muscle testing 
with the subanaerobic threshold exercise test (SATET) is a very specific measure for 
mitochondrial pathology (Nashef and Lane, 1989) but many mitochondrial myopathy paitents 
do not exhibit pathological values. Morphological, biochemical and molecular studies in 
tissue samples allow a diagnosis by the presence of suggestive histopathological findings 
such as RRF and ragged-blue fibers, cytochrome C oxidase (COX) depleted fibers, variously 
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formed mitochondria, abnormal cristae and intracristal crystalloid inclusions and the 
determination of disease-causing mutations in the mtDNA and/or nDNA (Di Mauro et al., 
1985; Milone and Wong, 2013). As demonstrated in two of our 6 patients, these typical 
histological signs of mitochondrial myopathy can be lacking despite presence of a 
mitochondrial disease (Milone and Wong, 2013). Molecular genetic analysis of mtDNA in 
tissues may demonstrate heteroplasmic deletions and point mutations. In addition, nDNA 
mutations need to be considered. For heteroplasmic mtDNA mutations, the degree of 
heteroplasmy needs to be quantified, but the pathological threshold is poorly defnied, 
particularly in mitochondrial cytopathy patients at advanaced age. This heteroplasmy, a 
canonical criteria for the pathogenitity, is not always given as also pathogenic homoplasmic 
mutations have been described (Wallace et al., 1988; Di Mauro, 2004).  
To provide proper patient management, treatment and genetic counseling, a clear diagnosis 
of mitochondrial cytopathies is necessary. Our results demonstrate that high-resolution 
respirometry measurements could represent a promising additional tool for the diagnosis of 
mitochondrial cytopathies. In vitro measurements as the present high-resolution respirometry 
allow the estimation of the functionality of specific steps implicated in mitochondrial 
metabolism by the use of various substrates, uncouplers and inhibitors. Such polarographic 
measurements of O2 consumption provide more essential information on innate 
mitochondrial function, as evaluations not only of isolated mitochondria but also of 
permeabilized cells are possible (Barrientos et al., 2009). In contrast to the isolation 
procedure, permeabilization of muscle fibers preserves mitochondrial morphology and 
integrity and allows the examination of the intact mitochondrial network. However, the 
definition of normal ranges of complex activites in skeletal muscle remains disputed and 
difficult. Thus, further studies to eliminate these variations and to validate high-resolution 
respirometry as a diagnostic measure are needed. 
In conclusion, mitochondrial myopathy led to diminished skeletal muscle mitochondrial 
volume density and  respiratory capacity of each individual complex that were related to 
reduced exercise capacity. The affected mitochondrial quantity and quality could be 
responsible for the impaired exercise capacity and could further aggravate exercise 
intolerance. Nonetheless, it cannot be excluded that these findings are simply due to physical 
inactivity as a cause of the disease-related exercise intolerance. However, the lower 
mitochondrial volume density was attended by a shift in skeletal muscle phenotype from type 
I to type II fibers, reflecting a possible compensation for the lower mitochondrial respiratory 
as well as exercise capacity. Finally, the clearly reduced mitochondrial respiratory capacity in 
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patients with mitochondrial myopathy compared to age- and gender-matched healthy 
controls proposes high-resolution respirometry measurements in permeabilized skeletal 
muscle fibers to be a promising additional diagnostic tool. 
 
Funding 
This work was supported by grants from the Zurich Center for Integrative Human Physiology 
(ZIHP) and Neuromuscular Research Association Basel (NeRAB). 
70 
 
References 
Aydin J, Andersson DC, Hanninen SL, Wredenberg A, Tavi P, Park CB, et al. Increased 
mitochondrial Ca2+ and decreased sarcoplasmic reticulum Ca2+ in mitochondrial 
myopathy. Hum Mol Genet 2009; 18(2): 278-88. 
Barrientos A, Fontanesi F, Diaz F. Evaluation of the mitochondrial respiratory chain and 
oxidative phosphorylation system using polarography and spectrophotometric 
enzyme assays. Curr Protoc Hum Genet 2009; Chapter 19: Unit19 3. 
Booth FW, Gollnick PD. Effects of disuse on the structure and function of skeletal muscle. 
Med Sci Sports Exerc 1983; 15(5): 415-20. 
Cohen BH, Gold DR. Mitochondrial cytopathy in adults: what we know so far. Cleve Clin J 
Med 2001; 68(7): 625-6, 9-42. 
Dandurand RJ, Matthews PM, Arnold DL, Eidelman DH. Mitochondrial disease. Pulmonary 
function, exercise performance, and blood lactate levels. Chest 1995; 108(1): 182-9. 
Di Mauro S. Mitochondrial medicine. Biochim Biophys Acta 2004; 1659(2-3): 107-14. 
Di Mauro S. Pathogenesis and treatment of mitochondrial myopathies: recent advances. 
Acta Myol 2010; 29(2): 333-8. 
Di Mauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo DC. Mitochondrial myopathies. Ann 
Neurol 1985; 17(6): 521-38. 
Enns GM, Hoppel CL, DeArmond SJ, Schelley S, Bass N, Weisiger K, et al. Relationship of 
primary mitochondrial respiratory chain dysfunction to fiber type abnormalities in 
skeletal muscle. Clin Genet 2005; 68(4): 337-48. 
Ferreira R, Vitorino R, Alves RM, Appell HJ, Powers SK, Duarte JA, et al. Subsarcolemmal 
and intermyofibrillar mitochondria proteome differences disclose functional 
specializations in skeletal muscle. Proteomics 2010; 10(17): 3142-54. 
Flaherty KR, Wald J, Weisman IM, Zeballos RJ, Schork MA, Blaivas M, et al. Unexplained 
exertional limitation: characterization of patients with a mitochondrial myopathy. Am J 
Respir Crit Care Med 2001; 164(3): 425-32. 
Gallanti A, Prelle A, Chianese L, Barbieri S, Jann S, Schiaffino S, et al. Congenital myopathy 
with type 2A muscle fiber uniformity and smallness. Neuropediatrics 1992; 23(1): 10-
3. 
Gineste C, Hernandez A, Ivarsson N, Cheng AJ, Naess K, Wibom R, et al. Cyclophilin D, a 
target for counteracting skeletal muscle dysfunction in mitochondrial myopathy. Hum 
Mol Genet 2015. 
Gosker HR, Hesselink MK, Duimel H, Ward KA, Schols AM. Reduced mitochondrial density 
in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007; 30(1): 73-9. 
Gouspillou G, Sgarioto N, Norris B, Barbat-Artigas S, Aubertin-Leheudre M, Morais JA, et al. 
The relationship between muscle fiber type-specific PGC-1alpha content and 
mitochondrial content varies between rodent models and humans. PLoS One 2014; 
9(8): e103044. 
71 
 
Gram M, Vigelso A, Yokota T, Hansen CN, Helge JW, Hey-Mogensen M, et al. Two weeks of 
one-leg immobilization decreases skeletal muscle respiratory capacity equally in 
young and elderly men. Exp Gerontol 2014; 58: 269-78. 
Hassani A, Horvath R, Chinnery PF. Mitochondrial myopathies: developments in treatment. 
Curr Opin Neurol 2010; 23(5): 459-65. 
Heinicke K, Taivassalo T, Wyrick P, Wood H, Babb TG, Haller RG. Exertional dyspnea in 
mitochondrial myopathy: clinical features and physiological mechanisms. Am J 
Physiol Regul Integr Comp Physiol 2011; 301(4): R873-84. 
Hildebrand IL, Sylven C, Esbjornsson M, Hellstrom K, Jansson E. Does chronic hypoxaemia 
induce transformations of fibre types? Acta Physiol Scand 1991; 141(3): 435-9. 
Holt IJ, Harding AE, Cooper JM, Schapira AH, Toscano A, Clark JB, et al. Mitochondrial 
myopathies: clinical and biochemical features of 30 patients with major deletions of 
muscle mitochondrial DNA. Ann Neurol 1989; 26(6): 699-708. 
Hoppeler H, Hudlicka O, Uhlmann E. Relationship between mitochondria and oxygen 
consumption in isolated cat muscles. J Physiol 1987; 385: 661-75. 
Howald H, Pette D, Simoneau JA, Uber A, Hoppeler H, Cerretelli P. Effect of chronic hypoxia 
on muscle enzyme activities. Int J Sports Med 1990; 11 Suppl 1: S10-4. 
Iqbal S, Ostojic O, Singh K, Joseph AM, Hood DA. Expression of mitochondrial fission and 
fusion regulatory proteins in skeletal muscle during chronic use and disuse. Muscle 
Nerve 2013; 48(6): 963-70. 
Jacobs RA, Flück D, Bonne TC, Burgi S, Christensen PM, Toigo M, et al. Improvements in 
exercise performance with high-intensity interval training coincide with an increase in 
skeletal muscle mitochondrial content and function. J Appl Physiol (1985) 2013; 
115(6): 785-93. 
Jacobs RA, Lundby C. Mitochondria express enhanced quality as well as quantity in 
association with aerobic fitness across recreationally active individuals up to elite 
athletes. J Appl Physiol (1985) 2013; 114(3): 344-50. 
Jacobs RA, Siebenmann C, Hug M, Toigo M, Meinild AK, Lundby C. Twenty-eight days at 
3454-m altitude diminishes respiratory capacity but enhances efficiency in human 
skeletal muscle mitochondria. FASEB J 2012; 26(12): 5192-200. 
Jeppesen TD, Orngreen MC, Van Hall G, Vissing J. Lactate metabolism during exercise in 
patients with mitochondrial myopathy. Neuromuscul Disord 2013; 23(8): 629-36. 
Jeppesen TD, Schwartz M, Olsen DB, Vissing J. Oxidative capacity correlates with muscle 
mutation load in mitochondrial myopathy. Ann Neurol 2003; 54(1): 86-92. 
Larsson NG, Oldfors A. Mitochondrial myopathies. Acta Physiol Scand 2001; 171(3): 385-93. 
Linderholm H, Müller R, Ringqvist T, Sornas R. Hereditary abnormal muscle metabolism with 
hyperkinetic circulation during exercise. Acta Med Scand 1969; 185(3): 153-66. 
Milone M, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab 2013; 110(1-
2): 35-41. 
72 
 
Moggio M, Colombo I, Peverelli L, Villa L, Xhani R, Testolin S, et al. Mitochondrial disease 
heterogeneity: a prognostic challenge. Acta Myol 2014; 33(2): 86-93. 
Morgan-Hughes JA, Schapira AH, Cooper JM, Holt IJ, Harding AE, Clark JB. The molecular 
pathology of respiratory-chain dysfunction in human mitochondrial myopathies. 
Biochim Biophys Acta 1990; 1018(2-3): 217-22. 
Muranaka H, Osari S, Fujita H, Kimura Y, Goto A, Imoto C, et al. Congenital familial 
myopathy with type 2 fiber hypoplasia and type 1 fiber predominance. Brain Dev 
1997; 19(5): 362-5. 
Nashef L, Lane RJ. Screening for mitochondrial cytopathies: the sub-anaerobic threshold 
exercise test (SATET). J Neurol Neurosurg Psychiatry 1989; 52(9): 1090-4. 
Picard M, Ritchie D, Wright KJ, Romestaing C, Thomas MM, Rowan SL, et al. Mitochondrial 
functional impairment with aging is exaggerated in isolated mitochondria compared to 
permeabilized myofibers. Aging Cell 2010; 9(6): 1032-46. 
Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron 
microscopy. J Cell Biol 1963; 17: 208-12. 
Rollins S, Prayson RA, McMahon JT, Cohen BH. Diagnostic yield muscle biopsy in patients 
with clinical evidence of mitochondrial cytopathy. Am J Clin Pathol 2001; 116(3): 326-
30. 
Rossignol R, Letellier T, Malgat M, Rocher C, Mazat JP. Tissue variation in the control of 
oxidative phosphorylation: implication for mitochondrial diseases. Biochem J 2000; 
347 Pt 1: 45-53. 
Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, et al. Biochemical and 
molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 
228(1): 35-51. 
Schapira AH. Mitochondrial disease. Lancet 2006; 368(9529): 70-82. 
Schmiedel J, Jackson S, Schafer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003; 
250(3): 267-77. 
Taivassalo T, Abbott A, Wyrick P, Haller RG. Venous oxygen levels during aerobic forearm 
exercise: An index of impaired oxidative metabolism in mitochondrial myopathy. Ann 
Neurol 2002; 51(1): 38-44. 
Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance 
training and detraining in mitochondrial myopathies due to single large-scale mtDNA 
deletions. Brain 2006; 129(Pt 12): 3391-401. 
Taivassalo T, Haller RG. Implications of exercise training in mtDNA defects--use it or lose it? 
Biochim Biophys Acta 2004; 1659(2-3): 221-31. 
Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports 
Exerc 2005; 37(12): 2094-101. 
Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of 
exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003; 
126(Pt 2): 413-23. 
73 
 
Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and 
treatment options. Med Sci Sports Exerc 2005; 37(12): 2086-93. 
Tryon LDV, A.; Memme, J.M.; Crilly, M.J.; Hood D.A. Recent advances in mitochondrial 
turnover during chronic muscle disuse. Integrative Medicine Research 2014; 3(4): 
161-71. 
Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human 
disease. Biochim Biophys Acta 2010; 1797(2): 113-28. 
Venhoff N, Lebrecht D, Pfeifer D, Venhoff AC, Bisse E, Kirschner J, et al. Muscle-fiber 
transdifferentiation in an experimental model of respiratory chain myopathy. Arthritis 
Res Ther 2012; 14(5): R233. 
Vissing J, Galbo H, Haller RG. Exercise fuel mobilization in mitochondrial myopathy: a 
metabolic dilemma. Ann Neurol 1996; 40(4): 655-62. 
Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283(5407): 1482-8. 
Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, et al. Mitochondrial DNA 
mutation associated with Leber's hereditary optic neuropathy. Science 1988; 
242(4884): 1427-30. 
Wenz T, Diaz F, Hernandez D, Moraes CT. Endurance exercise is protective for mice with 
mitochondrial myopathy. J Appl Physiol (1985) 2009; 106(5): 1712-9. 
West MJ. Estimating volume in biological structures. Cold Spring Harb Protoc 2012; 
2012(11): 1129-39. 
Wredenberg A, Wibom R, Wilhelmsson H, Graff C, Wiener HH, Burden SJ, et al. Increased 
mitochondrial mass in mitochondrial myopathy mice. Proc Natl Acad Sci U S A 2002; 
99(23): 15066-71. 
Zhong H, Roy RR, Siengthai B, Edgerton VR. Effects of inactivity on fiber size and 
myonuclear number in rat soleus muscle. J Appl Physiol (1985) 2005; 99(4): 1494-9. 
 
 
 
 
74 
 
Mitochondrial function in skeletal muscle of Huntington 
disease patients 
in preparation for submission 
 
Authors  
Saskia Maria Gehrig1,2,3, Jens Petersen3, Sebastian Frese3, Sandro Manuel Müller3,Violeta 
Mihaylova3, Maria Auer3,  Carsten Lundby1,2, Marco  Toigo4,5, Hans H. Jung1,3 
Addresses 
1Zurich Center for Integrative Human Physiology (ZIHP), Switzerland 
2Institute of Physiology, University of Zurich, Switzerland 
3Department of Neurology, University Hospital Zurich, Switzerland,  
4Institute of Human Movement Sciences and Sport, Exercise Physiology, Federal Institute of 
Technology Zurich, Zurich, Switzerland.  
5University of Zurich, Balgrist University Hospital, Department of Orthopaedics, Zurich, 
Switzerland 
Corresponding author 
Prof. Dr. med. Hans H. Jung  
Department of Neurology 
University Hopsital Zurich 
Frauenklinikstrasse 26 
CH-8091 Zurich 
Switzerland 
Tel: +41 44 255 55 45 
Email: hans.jung@usz.ch 
Running title 
Skeletal muscle physiology in Huntington disease 
75 
 
Abstract 
Purpose. Despite considerable progress in the comprehension of pathomechanisms of 
Huntington disease (HD) in the brain and central nervous system (CNS), the affection of 
peripheral tissue as skeletal muscle and possible related pathomechanisms remain elusive. 
Mitochondrial dysfunction has been proposed to be a major pathogenic factor. Thus, the aim 
of the present study was to investigate mitochondrial function in skeletal muscle HD patients. 
Methods. Skeletal muscle biopsies were obtained from 10 patients with diagnosed HD (54 ± 
7) and 11 age- and gender-matched healthy controls (56 ± 14) to determine skeletal muscle 
morphology and mitochondrial function. Results. Mitochondrial respiratory capacity of 
complex I (63.9 ± 13.1 vs. 80.6 ± 18.2 pmol O2 mg−1 s−1) and maximal oxidative 
phosphorylation capacity (88.9 ± 18.7 vs. 106.1 ± 18.4 pmol O2 mg−1 s−1) were impaired with 
HD (P < 0.05) and accompanied by a higher (P < 0.001) proportion of type I fibers (67.1 ± 9.2 
vs. 39.4 ± 23.3 %). Conclusion. HD seems to affect peripheral tissue as skeletal muscle by 
a shift in fiber phenotype and minor changes in mitochondrial function, potentially supporting 
mitochondrial dysfunction to be a pathogenic factor.  
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Abbreviations 
BMC, bone mineral content; CK, phosphocreatine kinase; CNS, central nervous system; 
COX, respiratory capacity of complex IV; CSA, cross-sectional area; DXA, dual-energy X-ray 
absorptiometry; E, electron transport system capacity; ETS, electron transport system; 
FCCP, carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; HD, Huntington disease; LN, 
leak respiration without adenylates; LOmy, oligomycin-induced leak respiration; mATPase, 
myofibrillar adenosinetriphosphatase; P, oxidative phosphorylation capacity; PCI, respiratory 
capacity of complex I; PCII, respiratory capacity of complex II; PETF, fatty acid oxidative 
capacity; 31P-MRS,  31P magnetic resonance spectroscopy; Ppeak, peak power output; ROX, 
residual oxygen consumption; UHDRS, Unified Huntington’s Disease Rating Scale; V̇O2peak, 
peak oxygen uptake; ww, wet weight. 
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Introduction 
Huntington disease (HD) is a hereditary neurodegenarative disorder characterized by motor 
disturbance, cognitive loss and psychiatric manifestations (Martin & Gusella, 1986). HD is 
caused by the expansion of a CAG repeat in exon 1 of the IT-15 gene encoding the protein 
huntingtin (The Huntington's Disease Collaborative Research Group, 1993). Although the 
genetic mutation causing HD had been identified, the mechanisms responsible for the 
pathology have remained widely unclear. As huntingtin was only known to be expressed 
throughout the brain and cetral nervous system (CNS), for many years attention focused only 
on the pathologic mechanisms in the brain. However, huntingtin is found also in peripheral 
tissues including skeletal muscle (The Huntington's Disease Collaborative Research Group, 
1993; Sharp et al., 1995). Despite the fact that HD is clinically characterized by a progressive 
movement disorder which affects motor control and could therewith also deteriorate skeletal 
muscle function and/or structure, the role of huntingtin and according pathomechanisms still 
remains elusive. Hence, thorough analysis of skeletal muscle properties offers a promising 
measure to disclose pathological mechanisms in peripheral tissue and may add to a better 
understanding of the general pathogenesis of this disorder. Moreover, the elucidation of 
potential pathologic processes may enhance the development of effective treatment 
approaches that are lacking so far.  
Particularly in the middle or late stages of the disease HD patients often report prominent 
and problematic weight loss and skeletal muscle wasting (Sanberg et al., 1981; Kirkwood et 
al., 2001) that can neither be explained by an inadequate caloric intake nor by excessive 
energy expenditure related to the disease itself (Hamilton et al., 2004; Turner et al., 2007). In 
addition to this clinical evidence of affected muscle tissue, there have been other signs of 
skeletal muscle alterations in HD patients but mainly in HD mouse models. Skeletal muscle 
atrophy that is reported in HD mouse model could be one reason for the weight loss and 
represents a significant pathological component of HD, also aggravating the movement 
disorder (Ribchester et al., 2004). The underlying mechanism for this atrophy and whether it 
is primary or secondary to the disease, however, is unknown. Another potential explanation 
for the weight loss could be abnormalities of the metabolism, especially impaired 
mitochondrial function (Lodi et al., 2000; Saft et al., 2005). Some HD patients reported 
diminished skeletal muscle mitochondrial oxidative metabolism (Lodi et al., 2000; Saft et al., 
2005) which supports the hypothesis of mitochondrial dysfunction as a potential factor 
involved in the pathogenesis of this disease. Collectively, studies on the effect of HD on 
peripheral tissue as skeletal muscle, the underlying mechanisms as well as its consequences 
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especially in humans are lacking. Therefore, we aimed to investigate potential alterations in 
skeletal muscle morphology and mitochondrial function of patients with HD to test the 
hypothesis that HD also affects and manifests in peripheral tissue. The present findings 
could offer new insights into the disease mechanism and thereby support the establishment 
of new therapeutic approaches.  
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Methods 
Ethical approval 
The present experimental protocol was approved by the Cantonal Ethics Committee of 
Zurich (KEK-Nr. 2009-0119) and was conducted in accordance with the Declarations of 
Helsinki. Participants were fully informed about the purposes, benefits and risks associated 
with this study and gave their written informed consent prior to the initiation of the 
experiments. Data of healthy controls were collected from two other studies of our laboratory 
investigating mitochondrial function in healthy individuals that however have not been 
published so far. 
Participants 
A total of 10 patients with the genetically verified diagnosis of HD (6 males and 4 females, 54 
± 7 y), and 11 age- and gender-matched healthy controls (7 males and 4 females, 56 ± 14 y), 
voluntarily participated in this study. Participants’ characteristics are presented in Table 2. 
Recruited patients (Table 1) were selected from a patient base followed at the 
neuromuscular research center (Department of Neurology, University Hospital Zurich) and 
matched by gender, age and as far as possible by physical activity patterns to healthy 
controls. Prior to any experiments, study participants were clinically examined and were 
screened to exclude any cardiac, respiratory or metabolic disease and/or any orthopedic 
pathologies. Serum phosphocreatine kinase (CK) levels needed to be lower than 300 U L−1 
and motor and cognitive skills of patients needed to be well enough to give written informed 
consent and to conduct a cycling exercise test (Table 1). Patients and controls were neither 
completely sedentary nor highly trained and none of them exhibited diabetes, coronary heart 
disease, peripheral vascular disease or clinically significant hyperlipidemia.  
Experimental design 
At baseline, clinical and exercise-physiological assessments were performed. Clinical 
assessments consisted of neurological examination, muscle strength examination, specific 
health questions and a skeletal muscle biopsy obtained from the m. vastus lateralis. 
Exercise-physiological assessments included a scan for body composition and an 
incremental exercise test for the determination of exercise capacity.  
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Body composition measurement 
Total mass, bone mineral content (BMC), fat mass, percentage body fat, as well as total and 
lean soft tissue mass of the leg were determined by performing dual-energy X-ray 
absorptiometry (DXA) measurements using a densitometer (Lunar iDXATM, GE Healthcare, 
Madison, WI, USA).  
Exercise testing 
Each study participant conducted an incremental exercise test on an electrically braked cycle 
ergometer until volitional exhaustion (Ergoselect 200K, Ergoline, Bitz, Germany) to determine 
peak O2 uptake (V̇O2peak) and peak power output (Ppeak). Pulmonary gas exchange and 
ventilation were continuously recorded during both exercise tests using an online gas 
collection system (Innocor™ M400, Innovision, Odense, Denmark), where O2 and CO2 
concentration were continuously measured and monitored as breath-by-breath values. The 
gas analysers and the flowmeter of the applied spirometer were calibrated prior to and after 
each test according to the manufacturer’s instructions. Throughout all cycling tests, heart rate 
was recorded (Polar S610i, Polar Electro, Kempele, Finland) and perceived exertion was 
interrogated by a Borgh Scale. The incremental cycling test consisted of a 3 min rest phase 
at 0 W, followed by exercise at 25 W with power increments of 25 W every 120 s until 
volitional fatigue. Pedal cadences were freely chosen by the participants but had to remain 
constant throughout the test and lay between 60 and 80 revolutions per minute (rpm). V̇O2peak 
was determined as the highest mean over a 10 s period.  
Skeletal muscle sampling 
After a coagulation test, skeletal muscle biopsies were obtained under standardized 
conditions from the m. vastus lateralis under local anesthesia (1 % lidocaine) of the skin and 
superficial muscle fascia, using the Bergström technique with a needle modified for suction. 
The biopsy was immediately dissected macroscopically free of fat and connective tissue and 
divided into sections for actual measurement of mitochondrial respiratory capacity and later 
histochemistry. The part of the biopsy for the determination of mitochondrial respiratory 
capacity was directly placed in ice-cold biopsy preservation solution. Muscle tissue for 
immunohistochemistry was instantly mounted in an embedding medium (Tissue-Tek®, 
Sakura, Zoeterwoude, The Netherlands), snap frozen in isopentane cooled to −160 °C with 
liquid nitrogen, and subsequently stored at −80 °C until further processing.  
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Mitochondrial respiration measurement 
Samples were prepared as described in detail previously (Jacobs et al., 2012). Summarised, 
after mechanical fiber separation, chemical permeabilization in biopsy preservation solution 
and washing in mitochondrial respiration medium 05, muscle bundles were blotted dry and 
measured for wet weight (ww) in a balance-controlled scale (XS205 DualRange Analytical 
Balance, Mettler-Toledo AG, Greifensee, Switzerland). Respiration measurements were 
subsequently performed in mitochondrial respiration medium 06. O2 consumption of the 
individual muscle tissue was thereby measured at 37 °C using the high-resolution Oxygraph-
2k (Oroboros, Innsbruck, Austria). Standardised instrumental and chemical calibrations were 
performed as recommended by the manufacturer and described previously (Jacobs et al., 
2012). O2 flux was automatically calculated by the software, accounting for nonlinear 
changes in the negative time derivative of the O2 concentration signal (DatLab, Oroboros, 
Innsbruck, Austria). Experiments were performed as duplicates in a hyperoxygenated 
environment in order to prevent any potential O2 diffusion limitation. Thereby, O2 
concentration ranged between 200 and 450 nmol mL−1 within the chambers.  
Respiratory titration protocol 
The respiratory measurement protocol was specific to the analysis of individual aspects of 
respiratory capacity and coupling control efficiency during several substrate states induced 
via separate titrations. All titrations were added in series as presented, whereby the 
concentrations of substrates, uncouplers and inhibitors used were based on prior 
experiments (Jacobs et al., 2012). The titration protocol was modified from previous 
protocols where they are described in detail (Jacobs et al., 2012). In short, leak respiration in 
absence of adenylates (LN) was induced with the addition of octanoyl carnitine (0.2 mM) and 
malate (2 mM). Specifically, LN represents the resting O2 consumption of an unaltered and 
intact electron transport system (ETS) free of adenylates. Maximal electron flow through 
electron-transferring flavoprotein and maximal fatty acid oxidative capacity (PETF) was 
subsequently determined following the addition of ADP (5 mM). Electron capacity through 
complex I (PCI) was then induced following the additions of pyruvate (5 mM) and glutamate 
(10 mM). Maximal oxidative phosphorylation capacity (P) was induced with the addition of 
succinate (10 mM). P thereby represents respiration that is resultant to saturating 
concentrations of ADP and substrate supply both for complex I and II. As an internal control 
for the integrity of the mitochondrial preparation, the mitochondrial outer membrane was 
assessed with the addition of cytochrome C (10 µM). Following, ATP synthase was inhibited 
by the titration of oligomycin (1 µM) that lead to oligomycin-induced leak respiration (LOmy). 
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LOmy represents the corresponding leak state to P. In LOmy the chemiosmotic gradient is at 
maximum because of maximal substrate supply and inhibition of complex V (ATP synthase). 
Additionally, O2 flux is at minimum and is representative of proton leak, slip, cation cycling 
and overall dyscoupling. By uncoupling ATP synthase from the electron transport chain with 
the step-wise titration (4 x 0.5 µM) of the proton ionophore carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone (FCCP) phosphorylative restraint of electron transport 
was assessed reaching ETS capacity (E). In order to inhibit CI and to assess electron flow 
specific to complex II (PCII) rotenone (0.5 µM) was added. PCII is thereby not influenced by the 
preceding addition of FCCP, which was verified with separate protocols in our laboratory. 
The addition of antimycin A (2.5 µM) that inhibits complex III allows the determination and 
correction of residual O2 consumption (ROX), which is indicative of non-mitochondrial O2 
consumption in the chamber. Finally, respiration measurements were terminated by 
simultaneous titration of ascorbate and TMPD to assess complex IV (COX) activity. 
Ascorbate and TMPD represent redox substrates that donate electrons directly to COX. 
Correction of O2 flux for the side reaction of auto-oxidation was conducted by chemical 
calibration experiments prior to the measurements. All respiratory states were expressed per 
mg ww (mass-specific respiratory capacity) and normalized to COX (mitochondrial-specific 
respiratory capacity), a biomarker of mitochondrial content (Larsen et al., 2012; Jacobs et al., 
2013).  
Histochemistry 
Consecutive 8 µm sections were cut on a microtome at −25 °C and mounted on glass cover 
slides for further histochemical analyses. The serial cryocut-cross-sections were stained 
using the myofibrillar adenosinetriphosphatase (mATPase) method after acid (pH 
4.6preincubation according to Item et al. (2011). For all analyses, only fibers fully encircled 
by adjacent fibers were evaluated using Adobe Photoshop Pro CS6 (Adobe Systems 
Incorporated, San Jose, CA, USA) and were classified according to their isoform into type I 
and type II fibers. Fiber cross-sectional area (CSA) was determined by encircling the 
boundaries of the muscle cells of each fiber type. Only fibers with a circularity higher than 0.7 
were considered for analysis (perfect circle = 1.0). 
Statistics 
All data are presented as mean ± SD in text and figures. For all statistical analyses, a value 
of P < 0.05 was considered significant. The statistical analysis was conducted using the 
software SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). After verification of normal 
83 
 
distribution of the data, unpaired samples t-tests were conducted to test the null hypothesis 
stating no difference between patients with HD and health controls. When data was not 
normally distributed, a Wilcoxon-Mann-Whitney-U test was performed instead. Spearman’s 
rank correlation coefficients were calculated to determine potential dependences of several 
variables. The number of patients and controls included in each data set are always 
indicated and can vary due to technical difficulties. 
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Results 
All participants completed the skeletal muscle biopsy procedure, the DXA measurement and 
the incremental cycling exercise test. There was no difference in age or weight between 
groups (Table 2), indicating appropriate matching of patients and participants.   
Oxygen kinetics and body composition  
V̇O2peak was similar in patients with HD vs. healthy controls (Table 2). In accordance, Ppeak did 
not differ (P = 0.219) between groups (Table 2). Moreover, there were no differences in body 
composition between patients and controls in any of the tested parameters (Table 2). 
Collectively, these findings suggest similar fitness level of patients and controls.  
Skeletal muscle fiber type distribution  
There was a clear transition in skeletal muscle fiber type from type II to type I fibers in 
patients with HD compared to healthy controls (Table 2). In contrast, there was no difference 
in CSA of any fiber type between patients and controls (Table 2), i.e. no atrophic sign in 
patients with HD was present.  
Skeletal muscle mitochondrial function and density 
Mass-specific maximal mitochondrial respiration specific to complex I and oxidative 
phoshorylative capacity (per mg ww) were 12 % and 9 % lower (P < 0.05) in patients with HD 
vs. healthy controls (Figure 1A). However, after normalizing mitochondrial respiratory 
capacity to COX activity, a biomarker of mitochondrial content (Larsen et al., 2012; Jacobs et 
al., 2013), all respiratory states specific to the five mitochondrial complexes were similar 
between groups (Figure 1B). Moreover, COX activity did not differ between groups, indicating 
similar mitochondrial content. 
Relations 
There was no correlation between UHDRS and V̇O2peak (ρ = −0.233; P = 0.546) or Ppeak (ρ = 
−0.218; P = 0.574). Simliarly, UDHRS did not correlate with PCI or P (ρ = 0.200; P = 0.606 or 
ρ = −0.033; P = 0.932). Furthermore, there was no correlation between fiber type distribution 
and UDHRS (ρ = 0.200; P = 0.606). However, UDHRS was negatively correlated (P < 0.05) 
to CSA of type II fibers (ρ = −0.886).  
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Fig 1. (A) Mass-specific mitochondrial respiratory capacity and (B) mitochondrial-specific respiratory 
capacity (normalized to COX) in patients with Huntington disease (HD, white bars) and healthy 
controls (black bars). LN, leak respiration without adenylates; PETF, fatty acid oxidative capacity; PCI, 
respiratory capacity of complex I; P, oxidative phosphorylation capacity; LOmy, oligomycin-induced leak 
respiration; E, electron transport system capacity; PCII, respiratory capacity of complex II; ROX, 
residual oxygen consumption; COX, respiratory capacity of complex IV. Values are mean ± SD. *P < 
0.05; nPatients = 10, nControl = 11 
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Table 1 Clinical and genetic characteristics of patients with Huntington disease 
patient sex age of onset (y) disease duration (y) UHDRS CAG repeats 
EHD 22 m 52 - 3 39 
EHD 24 m 40 20 37 41 
EHD 26 m 52 7 20 42 
EHD 27 m 37 5 7 43 
EHD 28 f 59 - 43 42 
EHD 29 f 53 - 6 38 
EHD 30 m - - 24 43 
EHD 31 f - - 1 38 
EHD 32 m 48 3 11 45 
EHD 33 f 56 6 28 41 
CAG repeats, cytosine-adenosine-guanosine repeats; UHDRS, Unified Huntington’s Disease Rating 
Scale 
87 
 
 
Table 2 Physiological characteristics of patients with Huntington disease (n = 10) and healthy controls 
(n = 11) 
 Patients controls P-value 
age (y) 54 ± 7 56 ± 14 0.674 
weight (kg) 77 ± 16 74 ± 12 0.635 
height (cm) 172 ± 8 173 ±7 0.719 
BMC (kg) 2.8 ± 0.5 2.8 ± 0.4 0.881 
fat mass (kg) 22.4 ± 8.4  18.2 ± 10.0 0.316 
lean mass (kg) 53.3 ± 11.5  47.8 ± 12.9 0.317 
lean mass legs (kg) 18.4 ± 4.3 20.0 ± 6.8 0.535 
total body fat (%) 29.4 ± 8.1  29.3 ± 5.2 0.973 
relative V̇O2peak (mL min−1 kg−1) 31.0 ± 6.6 34.6 ± 6.5 0.232 
Ppeak (W)  155 ± 50 182 ± 46  0.219 
Type I fibers (%) 67.1 ± 9.2  39.4 ± 23.3a  < 0.05 
Type II fibers (%) 32.9 ± 9.2  60.6 ± 23.3a < 0.05 
CSA type I fibers (µm2)  4134 ± 581 b 5191 ± 1549 a  0.193 
CSA type II fibers (µm2) 3652 ± 923 b 4596 ± 1403 a  0.193 
Values are represented as means ± SD. BMC, bone mineral content; CSA, cross-sectional area; Ppeak, 
peak power; relative V̇O2peak, peak oxygen uptake per kg body weight. a n = 10, b n = 7 
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Discussion 
The main finding of this study is a shift from type II fibers to type I fibers without atrophic 
signs in any of the fiber types. In line therewith, neither body composition nor exercise 
capacity differed between patients with HD and healthy controls. Mitochondrial respiratory 
capacity specific to complex I and maximal oxidative phosphorylation capacity per mg ww of 
tissue were slightly lower in patients with HD. However, when respiratory capacity was 
normalized to mitochondrial content, the difference disappeared. Despite higher type I fiber 
distribution, there was no indication for higher mitochondrial content with HD.  
The shift in skeletal muscle phenotype to more type I fibers could represent a compensation 
for the lower respiratory capacity of complex I and oxidative phosphorylation capacity, 
allowing the maintenance of exercise capacity. In the present study, mass-specific complex I 
respiratory capacity and maximal oxidative phosphorylation capacity were lower in patients 
with HD. Noteworthy, this is the first study that determines mitochondrial function in patients 
with HD by high-resolution respirometry, which allows the preservation of innate 
mitochondrial function in contrast to other previously applied methods (Lanza et al., 2011; 
Picard et al., 2011). This complex I deficiency has been previously described in three of four 
muscle biospies from symptomatic HD patients that showed no further muscle symptoms nor 
muscle wasting (Arenas et al., 1998). In contrast, mitochondrial content, represented by COX 
activity (Larsen et al., 2012; Jacobs et al., 2013), did not differ between HD patients and 
healthy controls and when mitochondrial respiratory capacity was normalized to it, there was 
no difference in the innate function of any of the mitochondrial complexes. These findings are 
also in line with previous findings (Turner et al., 2007; Ciammola et al., 2011) that found no 
difference in respiratory capacity specific to complex I to IV. However, when correlated to 
disease progression, they found a reduction in complex II/III activity, suggesting lower 
mitochondrial oxidative capacity with the course of the disease. Additionally, impaired 
mitochondrial function assessed by 31P magnetic resonance spectroscopy (31P-MRS) in 
muscle of HD patients (Koroshetz et al., 1997; Lodi et al., 2000; Saft et al., 2005) support the 
hypothesis that impaired mitochondrial function is involved in the pathogenesis of HD and 
could contribute to worsening of several clinical parameters as progressive 
neurodegeneration in HD. The pathophysiological mechanisms that could cause 
mitochondrial impairment remain speculative. It has been suggested (Arenas et al., 1998) 
that patients with large CAG repeats have elevated muscle mitochondrial DNA damage that 
could secondarily lead to mitochondrial respiratory chain defects. Further studies are 
however needed to strengthen these primary results. 
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Patients with HD disclosed no difference in weight or in body composition compared to age- 
and gender-matched healthy controls. These findings are in contrast with earlier reports of 
severe weight loss and skeletal muscle wasting, especially in the middle and late stages of 
this disease (Sanberg et al., 1981; Kirkwood et al., 2001). However, in support of our 
findings, more recent investigation on greater patient cohorts could not find a reduction in 
weight (Hamilton et al., 2004) or in body composition with HD (Pratley et al., 2000). Hence, 
weight loss seems not be a consistent feature of HD. Preserved lean mass (Table 2) and 
unaltered CSA of both fiber types further suggest that HD does not per se lead to skeletal 
muscle atrophy. However, as there was a correlation between UHDRS and CSA of type II 
and in consideration of previous studies (Kirkwood et al., 2001; Hamilton et al., 2004) onset 
of skeletal muscle atrophy with further disease progression in these patients cannot be 
excluded.  
Furthermore, the unchanged body composition was reflected by the comparable exercise 
capacity in patients and controls, which at first glance seems rather surprising. However, 
total exercise capacity has previously been shown to be normal in HD patients despite 
reduced Ppeak and V̇O2peak in symptomatic HD patients compared to healthy controls 
(Ciammola et al., 2011). Reasons for this minimal discrepancy to the present study could be 
lifestyle, as the present study participants overall reported a higher V̇O2peak and therefore 
were most likely more physically active than the study cohort of Ciammola et al. (2011). 
Usually, HD patients engage in less voluntary physical activity than healthy individuals due to 
the symptoms of their disease. Nonetheless, their daily free-living energy expenditure is 
similar to healthy controls because of a higher sedentary energy expenditure (Pratley et al., 
2000). It is suggested, that the resting energy expenditure is increased according to the 
choreaic movement disorder (Pratley et al., 2000). Moreover, chorea could lead to a similar 
skeletal muscle phenotype as endurance training (Strand et al., 2005). Hence, the choreaic 
movement disorder of HD patients could also be an explanation for the shift in muscle fiber 
type from type II to type I fibers reported in this study. Chronic low frequency stimulation of 
muscle contraction leasds to a transition from fast to slow fibers (Buller et al., 1960; Eken & 
Gundersen, 1988), indicating changes in electrical activity to be responsible for a switch in 
skeletal muscle phenotype (Berchtold et al., 2000; Flück & Hoppeler, 2003). Therefore, the 
transition in fiber type distribution towards more type I fibers with HD could be explained by 
an aberrant input from CNS manifesting in choreaic movement (Strand et al., 2005), which 
was however not tested in this study and remains to be investigated.  
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Conclusion 
This is the first study that investigates potential alterations in human skeletal muscle 
morphology and mitochondrial respiratory capacity of each individual complex in HD patients. 
HD resulted in a shift from type II fibers to type I fibers without atrophic signs in any of the 
fiber types. This transition in fiber type was accompanied by lower mitochondrial respiratory 
capacity specific to complex I and maximal oxidative phosphorylation capacity per mg ww of 
tissue. However, there was no difference in mitochondrial content with HD. In conclusion, 
skeletal muscle seems to be affected in patients with HD with a shift in skeletal muscle 
phenotype and minor mitochondrial alterations. Further studies investigating the underlying 
mechanism remain required.  
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3. Discussion and Outlook 
The aim of the present dissertation was to augment the understanding of skeletal muscle 
mitochondrial function and to contribute to a comprehensive conception of these organelles. 
Accordingly, skeletal muscle mitochondrial function and its relation to different other muscle 
physiological aspects were determined in healthy young and old fitness-level-matched 
individuals as well as in patients with MM and HD. As the results are discussed in detail in 
the corresponding manuscripts, the following section provides a summary of the key 
conclusions, listed separately for each study of this dissertation. The last subchapter will 
highlight the general conclusion and present an outlook for future research.   
 
3.1 Exercise efficiency is higher in old compared to young men at similar fitness level 
This study expands previous research in the field of aging and efficiency by accounting for 
fitness level of the young and old participants. The findings demonstrate higher EE with 
advancing age, indicating that impairments formerly related to age were biased by the 
drawbacks of physical inactivity accompanying a sedentary lifestyle. Additionally, 
mitochondrial fatty acid oxidative capacity was higher in old individuals and positively 
correlated to EE, suggesting that older individuals may rely more on fatty acid oxidation and 
are therefore more efficient. The higher capacity of fatty acid oxidation was further reflected 
by a lower respiratory exchange ratio with age. In contrast to our hypothesis, neither fiber 
type distribution nor mitochondrial content differed between old and young individuals. 
Similarly, maximal oxidative phosphorylation did not differ with age and was not related to 
EE. However, a potentially higher recruitment of ST fibers mirrored by a tendency towards 
lower FT fiber cross-sectional area in old participants could partly explain the higher reliance 
on fatty acid oxidation and thereby the higher EE with increasing age. Further research 
investigating additional influencing factors on EE and the interdependency of age is needed, 
as EE represents a key determinant of exercise capacity and thus mobility of the elderly.  
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3.2 Patients with mitochondrial myopathy exhibit diminished mitochondrial quantity 
and quality and a shift in skeletal muscle phenotype 
This study demonstrates that both mitochondrial volume density and intrinsic mitochondrial 
function were affected in patients with MM. In particular, maximal respiratory capacity of each 
single complex was lower with MM. Additionally, MM led to a shift in skeletal muscle 
phenotype towards more type II fibers and a tendency to general muscle fiber atrophy. 
Furthermore, V̇O2peak in patients with MM was reduced and correlated to mitochondrial 
volume density and maximal oxidative phosphorylation capacity. Hence, the affected 
mitochondrial quantity and quality might be responsible for the impaired exercise capacity 
and could thereby aggravate exercise intolerance. Nevertheless, this study could not clarify 
whether the disease per se led to mitochondrial impairments. Physical inactivity as a 
consequence of the disease-related exercise intolerance could as well have at least partly 
contributed to lower mitochondrial content and function with MM. Collectively, MM-related 
dysfunctions further promote exercise intolerance, which in turn seems to be a fundamental 
consequence of a defective respiratory chain due to pathogenic mutations of skeletal muscle 
mtDNA and/or nDNA. 
 
3.3 Mitochondrial function in skeletal muscle of Huntington disease patients 
This study extends previous investigations on potential alterations in peripheral tissue with 
HD by the examination of human skeletal muscle morphology and mitochondrial function 
specific to each separate complex in patients with HD. The main findings were a shift from 
type II fibers to type I fibers without atrophic signs in any of the fiber types. This translation in 
skeletal muscle phenotype with HD coincided with a lower mitochondrial respiratory capacity 
specific to complex I and maximal oxidative phosphorylation capacity per mg wet weight of 
tissue. However, despite higher type I fiber proportion in patients with HD, mitochondrial 
content did not differ. Additionally, when respiratory capacity was normalized to mitochondrial 
content there was no difference between groups. Collectively, the present findings indicate 
that skeletal muscle is affected in patients with HD, at least by a shift in skeletal muscle 
phenotype and minor mitochondrial alterations. Nevertheless, further research on the 
underlying mechanisms is required.  
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3.4 Conclusion 
Mitochondria are unique cell organelles representing the main protagonists of the human 
organism’s energy supply. By creating biologically accessible energy, these organelles 
maintain homeostasis as well as skeletal muscle function. Therefore, accurate functioning of 
mitochondria is crucial to human health. Defects in the human genome affecting 
mitochondrial proteins can result in impaired oxidative phosphorylation capacity, the 
generation of ROS and further impairment of skeletal muscle structure and function. This 
process is thought to play an important role in human aging and specific mitochondrial and 
other neurodegenerative diseases such as MM and HD. The present dissertation consists of 
three different studies aiming to generate a detailed overview on skeletal muscle 
mitochondrial function and its relation to specific skeletal muscle properties.  
In summary, mitochondrial fatty acid oxidative capacity is higher in advanced age and 
positively correlated to exercise efficiency. On the contrary, mitochondrial volume density 
and maximal respiratory capacity as well as skeletal muscle phenotype are not affected by 
aging, when fitness levels are maintained. Whereas mitochondrial quality and quantity are 
sustained with age, they are clearly diminished in MM. In particular, respiratory capacity of 
each individual complex is reduced with MM. Additionally, MM patients exhibit a shift towards 
more type II myofibers. These findings indicate that the disease per se may lead to reduced 
mitochondrial volume density and function, thereby causing the typical symptom of exercise 
intolerance. This in turn may potentially result in further physical inactivity and a sedentary 
lifestyle that aggravates diminished mitochondrial quantity and quality. Skeletal muscle 
(mitochondrial) properties are also affected in patients with HD. Compared to MM patients, 
patients with HD exhibit only slight reductions in mitochondrial respiratory capacity of 
complex I and maximal oxidative phosphorylation capacity. Respiratory capacities of all other 
complexes are not affected by this disease. In contrast to MM, HD patients demonstrate a 
shift from type II to more type I fibers without any alteration in mitochondrial volume density. 
Hence, both diseases seem to be associated with impaired aerobic energy supply, though to 
a varying degree, and apparently exhibit different compensatory mechanisms herefore.  
Together, these studies expand previous knowledge in this field and emphasize the 
relevance of proper mitochondrial function for human health. Alterations in any of the 
respiratory complexes may have considerable implications for older individuals and for 
patients with MM and HD, leading to even greater risk for further functional impairments. In 
order to develop effective lifestyle and treatment approaches to maintain mitochondrial 
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function and sustain or improve quality of life, further studies on mitochondrial characteristics 
and underlying mechanisms are required. 
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